75000 - Document - Document and Entity Information
link:presentationLink
link:calculationLink
link:definitionLink
75010 - Statement - Consolidated Balance Sheets
link:presentationLink
link:calculationLink
link:definitionLink
75020 - Statement - Consolidated Balance Sheets (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75030 - Statement - Consolidated Statements of Operations
link:presentationLink
link:calculationLink
link:definitionLink
75040 - Statement - Consolidated Statements of Operations (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
75050 - Statement - Consolidated Statements of Comprehensive income (Loss)
link:presentationLink
link:calculationLink
link:definitionLink
75060 - Statement - Consolidated Statements of Changes in Redeemable Non-Controlling Interests and Stockholders' Deficit
link:presentationLink
link:calculationLink
link:definitionLink
75070 - Statement - Consolidated Statements of Cash Flows
link:presentationLink
link:calculationLink
link:definitionLink
75080 - Statement - Consolidated Statements of Cash Flows (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
995455 - Disclosure - Cybersecurity Risk Management, Strategy and Governance
link:presentationLink
link:calculationLink
link:definitionLink
995465 - Disclosure - The Company
link:presentationLink
link:calculationLink
link:definitionLink
995475 - Disclosure - Summary of Significant Accounting Policies
link:presentationLink
link:calculationLink
link:definitionLink
995485 - Disclosure - Discontinued Operations and Divestiture
link:presentationLink
link:calculationLink
link:definitionLink
995495 - Disclosure - Collaboration Agreements, License Agreement and Revenues
link:presentationLink
link:calculationLink
link:definitionLink
995505 - Disclosure - Consolidated Variable Interest Entity - Fortis
link:presentationLink
link:calculationLink
link:definitionLink
995515 - Disclosure - Fair Value Measurements
link:presentationLink
link:calculationLink
link:definitionLink
995525 - Disclosure - Leases
link:presentationLink
link:calculationLink
link:definitionLink
995535 - Disclosure - Balance Sheet Components
link:presentationLink
link:calculationLink
link:definitionLink
995545 - Disclosure - Senior Secured Term Loan Facilities
link:presentationLink
link:calculationLink
link:definitionLink
995555 - Disclosure - Liability Related to Sale of Future Revenues
link:presentationLink
link:calculationLink
link:definitionLink
995565 - Disclosure - Product Development Obligations
link:presentationLink
link:calculationLink
link:definitionLink
995575 - Disclosure - Commitments and Contingencies
link:presentationLink
link:calculationLink
link:definitionLink
995585 - Disclosure - Equity and Stock-based Compensation
link:presentationLink
link:calculationLink
link:definitionLink
995595 - Disclosure - Net Loss Per Share
link:presentationLink
link:calculationLink
link:definitionLink
995605 - Disclosure - Income Taxes
link:presentationLink
link:calculationLink
link:definitionLink
995615 - Disclosure - Related Party Transactions
link:presentationLink
link:calculationLink
link:definitionLink
995625 - Disclosure - Segment and Geographic Information
link:presentationLink
link:calculationLink
link:definitionLink
995635 - Disclosure - Subsequent Event
link:presentationLink
link:calculationLink
link:definitionLink
995645 - Disclosure - Schedule II - Valuation and Qualifying Accounts
link:presentationLink
link:calculationLink
link:definitionLink
995655 - Disclosure - Summary of Significant Accounting Policies (Policies)
link:presentationLink
link:calculationLink
link:definitionLink
995665 - Disclosure - Discontinued Operations and Divestiture (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995675 - Disclosure - Collaboration Agreements, License Agreement and Revenues (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995685 - Disclosure - Exclusive License and Option to Acquire Fortis Therapeutics (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995695 - Disclosure - Equity Method Investment - Variable Interest Entity (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995705 - Disclosure - Fair Value Measurements (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995715 - Disclosure - Leases (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995725 - Disclosure - Balance Sheet Components (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995735 - Disclosure - Senior Secured Term Loan Facilities (Table)
link:presentationLink
link:calculationLink
link:definitionLink
995745 - Disclosure - Liability Related to Sale of Future Revenues (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995755 - Disclosure - Commitments and Contingencies (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995765 - Disclosure - Equity and Stock-based Compensation (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995775 - Disclosure - Net Loss Per Share (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995785 - Disclosure - Income Taxes (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995795 - Disclosure - Segment and Geographic Information (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995805 - Disclosure - The Company - Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995815 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995825 - Disclosure - Discontinued Operations and Divestiture - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995835 - Disclosure - Discontinued Operations and Divestiture - Schedule of Financial Results of Discontinued Operations (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995845 - Disclosure - Discontinued Operations and Divestiture - Schedule of Carrying Value of Assets and Liabilities of Discontinued Operations (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995855 - Disclosure - Discontinued Operations and Divestiture - Schedule of Significant Non-cash Items and Capital Expenditures for Discontinued Operations (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995865 - Disclosure - Collaboration Agreements, License Agreement and Revenues - Astellas Agreements - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995875 - Disclosure - Collaboration Agreements, License Agreement and Revenues - Accounting for the Astellas Agreements - Additional Information 2 (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995885 - Disclosure - Collaboration Agreements, License Agreement and Revenues - AstraZeneca Agreements - Additional Information 1 (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995895 - Disclosure - Collaboration Agreements, License Agreement and Revenues - Accounting for the AstraZeneca Agreements - Additional Information 3 (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995905 - Disclosure - Collaboration Agreements, License Agreement and Revenues - Roll-forward of Related Contract Liabilities (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995915 - Disclosure - Collaboration Agreements, License Agreement and Revenues - Drug Product Revenue - Summary of Drug Product Revenue (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995925 - Disclosure - Collaboration Agreements, License Agreement and Revenues - Drug Product Revenue - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995935 - Disclosure - Equity method investment - Variable Interest Entity - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995945 - Disclosure - Equity method investment - Variable Interest Entity - Summary of Equity Method Investment (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995955 - Disclosure - Fair Value Measurements - Fair Values of Financial Assets Measured on Recurring Basis (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995965 - Disclosure - Fair Value Measurements - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995975 - Disclosure - Leases - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995985 - Disclosure - Leases - Schedule of Lease Assets and Related Lease Liabilities (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995995 - Disclosure - Leases - Components of Lease Expense (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996005 - Disclosure - Leases - Schedule of Lease Term and Discount Rate (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996015 - Disclosure - Leases - Schedule of Supplemental Cash Flow Information Related to Leases (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996025 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996035 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities (Detail) 2
link:presentationLink
link:calculationLink
link:definitionLink
996045 - Disclosure - Consolidated Variable Interest Entity - Fortis - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996055 - Disclosure - Balance Sheet Components - Schedule of Cash and Cash Equivalents (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996065 - Disclosure - Balance Sheet Components - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996075 - Disclosure - Balance Sheet Components - Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Available-for-Sale Investments (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996085 - Disclosure - Balance Sheet Components - Summary of Available for Sale Securities in Unrealized Loss Position, Fair Value and Gross Unrealized Loss By Length of Time Security in Continual Unrealized Loss Position (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996095 - Disclosure - Balance Sheet Components - Summary of Available for Sale Securities in Unrealized Loss Position, Fair Value and Gross Unrealized Loss By Length of Time Security in Continual Unrealized Loss Position (Detail) 2
link:presentationLink
link:calculationLink
link:definitionLink
996105 - Disclosure - Balance Sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996115 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996125 - Disclosure - Balance Sheet Components - Schedule of Accrued and Other Current Liabilities (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996135 - Disclosure - Balance Sheet Components - Schedule of Other Long-term Liabilities (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996145 - Disclosure - Liability Related to Sale of Future Revenues - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996155 - Disclosure - Liability Related to Sale of Future Revenues - Schedule of Activity of Liability Related to Sale of Future Revenues (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996165 - Disclosure - Senior Secured Term Loan Facilities - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996175 - Disclosure - Senior Secured Term Loan Facilities - Summary of Senior Secured Term Loan Facilities (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996185 - Disclosure - Liability Related to Sale of Future Royalties - Schedule of Revenue Payment Cap Maturity (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996195 - Disclosure - Product Development Obligations - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996205 - Disclosure - Commitments and Contingencies - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996215 - Disclosure - Equity and Stock-based Compensation - Common Stock - Additional information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996225 - Disclosure - Equity and Stock-based Compensation - Summary of Common Stock Reserved for Future Issuance (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996235 - Disclosure - Equity and Stock-based Compensation -At-the-Market Program-Additional Information (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996245 - Disclosure - Equity and Stock-based Compensation - Stock Plans - Additional information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996255 - Disclosure - Equity and Stock-based Compensation - Stock Plans - Summary of Stock Option Transactions (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996265 - Disclosure - Equity and Stock-based Compensation - Summary of RSU,PRSU and TSR Awards (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996275 - Disclosure - Equity and Stock-based Compensation - Employee Stock Purchase Plan - Additional information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996285 - Disclosure - Equity and Stock-based Compensation - Schedule of Recorded Stock-Based Compensation Expense (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996295 - Disclosure - Equity and Stock-based Compensation - Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Employee Stock Purchase Plans (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996305 - Disclosure - Equity and Stock-based Compensation - Stock-Based Compensation - Additional information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996315 - Disclosure - Equity and Stock-based Compensation - Warrants - Additional information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996325 - Disclosure - Equity and Stock based compensation - Schedule of Assumptions used to Estimate Fair Value of TSR Awards (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996335 - Disclosure - Equity and Stock-based Compensation - Subsidiary Stock and Non-Controlling Interests - Additional information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996345 - Disclosure - Net Loss Per Share - Schedule of Weighted Impacts of Outstanding Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996355 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996365 - Disclosure - Income Taxes - Schedule of Components of Provision For Income Taxes (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996375 - Disclosure - Income Taxes - Schedule of Reconciliation Between Statutory Federal Income Tax Rate and Effective Tax Rate (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996385 - Disclosure - Income Taxes - Schedule of Significant Components of Deferred Tax Assets (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996395 - Disclosure - Income Taxes - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996405 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amounts of Unrecognized Income Tax Benefits (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996415 - Disclosure - Related Party Transactions - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996425 - Disclosure - Segment and Geographic Information - Additional information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996435 - Disclosure - Segment and Geographic Information - Schedule of Revenue by Geographic Area (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996445 - Disclosure - Segment and Geographic Information - Schedule of Customer Concentration by Collaboration Partners (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996455 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
Vested, Weighted Average Fair value at Grant
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Proceeds from Sale of Property, Plant, and Equipment, Total
Proceeds from sale of property and equipment
Proceeds from Sale of Property, Plant, and Equipment
Accounts Receivable from Distributors [Member]
Accounts Receivable From Distributors [Member]
Accounts receivable from distributors.
Warrants exercised, Shares
Warrant Exercised During Period Shares
Warrant exercised during period shares.
Foreign
Income (Loss) from Continuing Operations before Income Taxes, Foreign
Loss from continuing operations
Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
Concentration Risk Type
Concentration Risk Type [Axis]
Liability Related to Sale of Future Revenues
Liability Related To Sale Of Future Revenues [Policy Text Block]
Liability related to sale of future revenues.
Clinical and Development Milestone [Member]
Clinical Development Milestones [Member]
Clinical development milestone.
Less: Initial issuance costs
Initial Issuance Costs Related To Sale Of Future Revenues
Initial issuance costs related to sale of future revenues.
Finance Lease, Liability, Total
Present value of lease liabilities
Finance lease liability
Finance Lease, Liability
Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Modification of Contract
Cumulative catch-up net adjustment
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Finance Lease, Liability, to be Paid, Year Four
2027
Preferred stock, shares issued
Preferred Stock, Shares Issued
Balance Sheet Location
Statement of Financial Position Location, Balance [Domain]
Disposal Group, Including Discontinued Operation, Inventory, Current
Inventories
Debt Instrument, Premium and Fees
Debt instrument, premium and fees.
API Shipment [Member]
A P I Shipment [Member]
API shipment.
Increase (Decrease) in Accounts Payable, Total
Increase (Decrease) in Accounts Payable
Accounts payable
Revision of Prior Period [Axis]
HiFiBiO Agreement [Member]
Hi Fi Bi O Agreement [Member]
HiFiBiO agreement.
Astellas agreements.
Astellas Agreement [Member]
Astellas Collaboration Agreement [Member]
Astellas [Member]
Summary of Senior Secured Term Loan Facilities
Schedule of Long-Term Debt Instruments [Table Text Block]
Plan Name [Axis]
Plan Name
Available for sale securities in continual unrealized loss position, 12 months or more, estimated fair value
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer
Equity [Abstract]
Entity Current Reporting Status
Entity Current Reporting Status
Japan [Member]
JAPAN
Schedule of Lease Assets and Related Lease Liabilities
Schedule Of Lease Assets And Related Lease Liabilities Table [Text Block]
Schedule of lease assets and related lease liabilities.
Dividends Payable, Amount Per Share
Dividends per share
Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net
Accounts receivable, net
Level 2 [Member]
Fair Value, Inputs, Level 2 [Member]
Net deferred tax assets
Deferred Tax Assets, Net of Valuation Allowance
Commitments and Contingencies
Commitments and Contingencies Disclosure [Text Block]
Bonus depreciation percentage
Bonus Depreciation Percentage
Bonus depreciation percentage.
Common stock, shares authorized
Common Stock, Shares Authorized
Disposal group, including discontinued operation, cumulative currency translation adjustments.
Disposal Group, Including Discontinued Operation, Cumulative Currency Translation Adjustments
Discontinued operatiion cumulative currency translation adjustments
Investments
Investment, Policy [Policy Text Block]
Product and Service
Product and Service [Axis]
Preferred stock, voting rights
Preferred Stock, Voting Rights
Document Fiscal Period Focus
Document Fiscal Period Focus
Total future lease payments
Finance Lease, Liability, to be Paid
debt interest rate
Interest rate on product development advances
Debt Instrument, Interest Rate, Stated Percentage
Revenue:
Revenue from Contract with Customer [Abstract]
Entity Shell Company
Entity Shell Company
Other
Other Accrued Liabilities, Current
SEC Schedule, 12-09, Valuation Allowances and Reserves Type
SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]
Total cash and cash equivalents
Cash and cash equivalents
Cash and Cash Equivalent
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Weighted average number of common shares used to calculate net income (loss) per share:
Preferred stock redemption percentage
Preferred Stock, Redemption Terms
Accrued product development costs excluding interest
Accrued Product Development Costs Excluding Interest
Accrued Product Development Costs Excluding Interest.
Drug Product Revenue [Member]
Drug product revenue.
Drug Product Revenue, Net [Member]
Drug Product Revenue [Member]
Beyond 2027
Revenue Payment Cap Amount Due After Year Five
Revenue payment cap amount due after year five.
Research and Development Arrangement, Contract to Perform for Others, Type
Research and Development Arrangement, Contract to Perform for Others, Type [Axis]
Accrued and other liabilities from related party
Increase (Decrease) in Accounts Payable, Related Parties
Recently Issued Accounting Guidance Not Yet Adopted
Recently Issued Accounting Guidance Not Yet Adopted Policy [Text Block]
Recently issued accounting guidance not yet adopted.
Cybersecurity Risk Management, Strategy, and Governance [Abstract]
Common stock, shares issued
Common Stock, Shares, Issued
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]
Shared development costs
Shared Development Costs
Represents the total amount of development costs that will be shared under collaborative agreement.
Cybersecurity Risk Board of Directors Oversight [Text Block]
Statement [Table]
Statement [Table]
Increase due to current year position
Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions
Operating leases
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Long-term Purchase Commitment, Category of Item Purchased
Long-Term Purchase Commitment, Category of Item Purchased [Domain]
Weighted average fair value of stock options granted
Weighted average estimated fair value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Depreciation Expense for Continuing Operations
Depreciation expense for continuing operations.
Depreciation expense for continuing operations
Percentage of fair value exercise price grant date
Percentage of fair value exercise price grant date
Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent
Disposal Group, Including Discontinued Operation, Cash Consideration
Disposal group, including discontinued operation, cash consideration.
Discontinued operation consideration in cash
Statement [Line Items]
Statement [Line Items]
Business Acquisition, Acquiree
Business Combination [Domain]
Nonconsolidated Investees, Other [Member]
Nonredeemable NCI [Member]
Debt instrument accrued interest.
Debt Instrument Accrued Interest
Accrued interest
Expired, Weighted Average Exercise Price per Share
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
Warrants [Member]
Warrant [Member]
Entity Filer Category
Entity Filer Category
Non-cash: Right-of-use assets obtained in exchange for new lease liabilities:
Non Cash Right Of Use Assets Obtained In Exchange For New Lease Liabilities [Abstract]
Non cash right of use assets obtained in exchange for new lease liabilities.
Variable Interest Entity Disclosure [Text Block]
Consolidated Variable Interest Entity - Fortis
Schedule of Inventory by Geographic Area
Inventory By Geographic Areas Table [Text Block]
Inventory by geographic areas.
Selling, General and Administrative Expenses
Selling, General and Administrative Expenses, Policy [Policy Text Block]
Liabilities and Equity
Total liabilities, redeemable non-controlling interests and deficit
Debt Instrument [Line Items]
Debt Instrument [Line Items]
Unrestricted cash and cash equivalent balance maintain in accounts.
Unrestricted Cash And Cash Equivalent Balance Maintain In Accounts
Unrestricted cash and cash equivalent balance required to maintain in accounts
Commercial sales and other events milestone
Commercial Sales And Other Events Milestone
Commercial sales and other events milestone.
Credit Concentration Risk [Member]
Credit Concentration Risk [Member]
Schedule Of Leases [Line Items]
Schedule Of Leases [Line Items]
Schedule of leases.
Exercisable, Weighted Average Exercise Price per Share
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Cost of goods sold
Disposal Group, Including Discontinued Operation, Costs of Goods Sold
Finance leases
Increase (Decrease) in Right of use Asset Obtained in Exchange for Finance Lease Liability.
Increase (decrease) in right-of-use asset obtained in exchange for finance lease liability.
Long-Lived Tangible Asset
Long-Lived Tangible Asset [Axis]
Finance Lease, Liability, to be Paid, Year Three
2026
API and bulk drug product price true-up
Accrued API and bulk drug product price true-up current
Accrued API and bulk drug product price true-up current.
Increase in valuation allowance
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Percentage of outstanding shares acquired
Business Combination, Voting Equity Interest Acquired, Percentage
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]
Latest Tax Year [Member]
Latest Tax Year [Member]
Series G [Member]
Series G Preferred Stock [Member]
Lessee, Operating Lease, Option to Terminate
Lessee, Operating Lease, Option to Terminate
Payment Cap Date on or after January 1, 2029 [Member]
Payment cap date on or after January one two thousand twenty nine [Member]
Payment cap date on or after January one two thousand twenty nine.
Assets fair value disclosure
Cash and Cash Equivalents, Fair Value Disclosure
U.S. government bonds
US Government Securities, at Carrying Value
Less: Valuation allowance
Deferred Tax Assets, Valuation Allowance
Tax at statutory federal rate
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent
U.S. federal income tax rate
Reversal of accrued co-promotion expenses
Reversal Of Accrued Co Promotion Expenses
Reversal of accrued co-promotion expenses.
Percentage of product manufacturing costs until manufacturing technology fully transferred
Percentage Of Product Manufacturing Costs Until Manufacturing Technology Fully Transferred
Percentage of product manufacturing costs until manufacturing technology fully transferred.
Transfers of assets from level 2 to 1
Fair Value Assets Level2 To Level1 Transfer Amount
Fair value assets level2 to level1 transfer amount.
Intangible assets
Deferred Tax Assets Intangible Assets
Deferred tax assets intangible assets.
Cybersecurity Risk Management Third Party Engaged [Flag]
Documents Incorporated by Reference
Documents Incorporated by Reference [Text Block]
Total
Effective Income Tax Rate Reconciliation, Percent
Employee stock options [Member]
Convertible promissory note
Convertible Debt Securities [Member]
Income Tax Rate Reconciliation Discontinued Operations
Income tax rate reconciliation discontinued operations.
Discontinued operations, Amount
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]
Burdened manufacturing costs
Manufacturing Costs
Income Tax Authority
Income Tax Jurisdiction [Axis]
Available for sale investments contractual maturities
Available for Sale Investments Contractual Maturity
Available for sale investments contractual maturity.
Geographical
Geographical [Domain]
Liquidity and Going Concern
Liquidity and Going Concern Policy [Policy Text Block]
Liquidity and going concern policy.
Asset-backed securities [Member]
Asset-Backed Securities [Member]
Schedule II - Valuation and Qualifying Accounts
SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]
RIFA [Member]
Revenue Interest Financing Agreement [Member]
Revenue Interest Financing Agreement.
Revenue Interest Financing Agreement [Member]
Summary of Outstanding Non-cancelable Purchase Obligations
Recorded Unconditional Purchase Obligations [Table Text Block]
Schedule of Inventory
Schedule of Inventory, Current [Table Text Block]
Accounts receivable net current related parties.
Accounts Receivable Net Current Related Parties
Accounts receivable from related parties
Aggregate considerations received
Collaborative Arrangement Aggregate Consideration
Collaborative arrangement aggregate consideration.
Issuance cost
Debt Issuance Costs, Net, Total
Debt Issuance Costs, Net
Deduction
Contract With Customer Liability Deduction
Contract with customer liability deduction.
Cash paid for transaction costs related to sale of future revenues
Transaction costs related to sale of future revenues
Cash paid for transaction costs related to sale of future revenues
Payments For Transaction Costs Related To Sale Of Future Revenues
Payments for transaction costs related to sale of future revenues.
Debt Instrument, Interest Rate During Period
Interest rate per annum
Repayments of finance lease liabilities
Financing cash flows from finance leases
Repayments Of Finance Lease Liabilities
Repayments of finance lease liabilities.
Summary of Significant Accounting Policies
Significant Accounting Policies [Text Block]
Property Plant And Equipment [Line Items]
Property, Plant and Equipment [Line Items]
Expiration year two thousand twenty six.
Expiration Year Two Thousand Twenty Six [Member]
Expiration Year 2026 [Member]
Bank of Finland Interest Rate [Member]
Bank Of Finland Interest Rate [Member]
Bank of Finland interest rate.
TSR [Member]
Total Shareholder Return Awards [Member]
Total shareholder return awards.
Schedule of Cash and Cash Equivalents
Schedule of Cash and Cash Equivalents [Table Text Block]
Derecognized [Member]
Derecognized.
Derecognized
Maximum sales milestones receivable.
Maximum Sales Milestones Receivable
Maximum sales milestones receivable
Liability related to sale of future royalties.
Liability Related to Sale of Future Royalties
Liability Related To Sale Of Future Royalties [Text Block]
Granted, Shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross
Other Than Temporary Impairment Loss Securities Available for Sale
Other than temporary impairment loss securities available for sale.
Other-than-temporary impairment loss
Repayment description
Repayment description.
Repayment Description
Cybersecurity Risk Management, Strategy, and Governance [Table]
Accrued and Other Current Liabilities [Member]
Accrued And Other Current Liabilities [Member]
Accrued and other current liabilities.
Charged (Credited) to Statement of Operation
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense
Contract Liabilities [Member]
Contract Liabilities [Member]
Contract liabilities,
Equity investments [Member]
Equity Securities [Member]
Operating lease liabilities, current
Increase Decrease In Operating Lease Liabilities Current
Increase (decrease) in operating lease liabilities, current.
Investment, Name [Axis]
Employee stock purchase plans [Member]
Share-Based Payment Arrangement [Member]
Deferred revenue non-current to related party
Due To Related Parties Deferred Revenue Noncurrent
Due to related parties deferred revenue noncurrent.
Net loss per share - basic
Earnings Per Share, Basic
Net income (loss) per share - basic
Disposal group, including discontinued operation, hold back amount to offset final net cash adjustments
Disposal group, including discontinued operation, hold back amount to offset final net cash adjustments.
Discontinued operation hold back amount to offset final net cash adjustments
Other Revenue - Contract Manufacturing [Member]
Development Revenue [Member]
Development and Other Revenue [Member]
Development and other revenue.
Product development obligations
Accrued Product Development Costs
Represents the long-term portion of the outstanding principal and accrued interest of advances in the form note agreements received by the entity to fund various product development efforts.
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total
Foreign currency translation adjustments
Foreign currency translation adjustments
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax
Stock options outstanding
Outstanding, Beginning Balance, Shares
Outstanding, Ending Balance, Shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Summary of Amortized Cost, Gross Unrealized Holding Gains or Losses, and Fair Value of Investments
Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property
Loss on disposal of property and equipment
Payment for Contingent Consideration Liability, Investing Activities
Contingent payment associated with business acquisition
Total interest and other, net
Interest Income (Expense), Nonoperating
Other liabilities current due to related parties.
Other Liabilities Current Due to Related Parties
Accrued and other current liabilities to related party
Total current liabilities
Liabilities, Current
Disposal Group, Including Discontinued Operation, Accounts Payable, Current
Accounts payable
Accumulated amortization
Finance Lease Accumulated Amortization
Finance lease accumulated amortization.
Increase (Decrease) in Accounts Receivable
Accounts receivable, net
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Lessee, Operating Lease, Liability, to be Paid, Year Five
2028
Other, Amount
Effective Income Tax Rate Reconciliation, Cross-Border, Other, Amount
Entity Wide Revenue Major Customer [Line Items]
Revenue, Major Customer [Line Items]
Federal [Member]
Domestic Tax Jurisdiction [Member]
Deductions, Net
SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction
Effective Income Tax Rate Reconciliation [Table]
Increase due to prior positions
Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions
Accounting Standards Update
Accounting Standards Update [Axis]
Debt financing agreement.
Debt Financing Agreement [Member]
Stock-based compensation expense
Effective Income Tax Rate Reconciliation Deduction Expense Share Based Compensation Cost
Effective income tax rate reconciliation deduction expense share based compensation cost.
Restructuring and Related Cost, Number of Positions Eliminated, Period Percent
Restructuring plan, expected reduction to workforce, percentage
Payment Cap Date in 2031 [Member]
Payment cap date in two thousand thirty one [Member]
Payment cap date in two thousand thirty one.
Entity Small Business
Entity Small Business
Retained Earnings (Accumulated Deficit), Total
Accumulated deficit
Retained Earnings (Accumulated Deficit)
Stock-based compensation
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost
Nonmonetary Transaction Type [Axis]
Liability related to sale of future revenues, non-current
Liability Related To Sale Of Revenues NonCurrent
Liability related to sale of revenues noncurrent.
Summary of Common Stock Reserved for Future Issuance
Schedule Of Shares Of Common Stock Reserved For Future Issuance Table [Text Block]
Schedule of shares of common stock reserved for future issuance.
Entity Well-known Seasoned Issuer
Entity Well-known Seasoned Issuer
Common stock reserved for future issuance, Description
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Other Increases (Decreases) in Period, Description
Forfeited, Shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Disposal Group Including Discontinued Operation Accounts Payable And Accrued Liabilities Noncurrent
Disposal group including discontinued operation accounts payable and accrued liabilities noncurrent.
Accrued and other current liabilities
Foreign
Current Foreign Tax Expense (Benefit)
Cost, Product and Service [Extensible List]
Cost, Product and Service [Extensible Enumeration]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of sales return
Description Of Sales Return
Description of sales return.
Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain]
Recently Adopted Accounting Guidance [Policy Text Block]
Recently Adopted Accounting Guidance.
Recently Adopted Accounting Guidance
Lease Contractual Term
Lease Contractual Term [Axis]
Leases [Abstract]
Highly liquid investment maturity period
Highly Liquid Investment Maturity Period
Highly liquid investment maturity period.
Contract with Customer, Liability, Total
Deferred revenues from associated contracts
Deferred Revenue
Deferred revenue
Contract with Customer, Liability
Balance at December 31, 2024
Balance at December 31, 2025
Lessee, operating lease, expiration period
Lessee Operating Lease Expiration Period
Lessee, operating lease, expiration period.
Lessee Lease Description [Line Items]
Lessee, Lease, Description [Line Items]
Amendment Flag
Amendment Flag
Two Thousand And Twenty Four Equity Incentive Plan [Member]
2024 Equity Incentive Plan.
2024 Equity Incentive Plan
Product and Service
Product and Service [Domain]
Net Cash Held in China [Member]
Net cash held in China.
Effective Income Tax Rate Reconciliation, Deduction, Percent, Total
Deduction limitation on executive compensation
Effective Income Tax Rate Reconciliation, Deduction, Percent
Tax at statutory federal rate, Amount
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Foreign subsidiaries [Member]
Geographic Distribution, Foreign [Member]
Discontinued Operation, Name
Discontinued operations name
Additional consideration based on net sales description
Additional Consideration Based On Net Sales
The amount of additional consideration based on net sales of product as defined under a collaboration agreement.
Schedule of Assumptions used to Estimate Fair Value of Stock Options Granted and Employee Stock Purchase Plans
Schedule Of Share Based Payment Award Stock Options And Employee Stock Purchase Plan Valuation Assumptions Table [Text Block]
Schedule of share based payment award stock options and employee stock purchase plan valuation assumptions.
Delayed Draw Term Loan (DDTL) [Member]
Delayed Draw Term Loan [Member]
Proceeds from Sale, Maturity and Collection of Investments, Total
Proceeds from maturities of investments
Proceeds from Sale, Maturity and Collection of Investments
Interest on lease liabilities
Finance Lease, Interest Expense
Disposal Group, Including Discontinued Operation, Assets, Current
Total current assets held for sale
Current assets held for sale
Liabilities and Equity [Abstract]
Liabilities, redeemable non-controlling interests and deficit
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
Trade Accounts Receivable
Accounts Receivable [Policy Text Block]
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Net cash used in operating activities
License and milestone revenue from a related party
License Fees And Milestones Revenue
Revenue from multiple-deliverable arrangements that include licensing fees and services revenue and the amount of consideration recognized during the period for milestones. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, non-specified, services during the reporting period.
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description
Common Shares [Member]
Common Stock [Member]
Common Stock [Member]
Initial upfront payment
Initial Upfront Payment
Upfront payment.
Cybersecurity Risk Role of Management [Text Block]
Deferred revenues from associated contracts
Deferred Revenues From Associated Contracts
Deferred revenues from associated contracts.
Weighted average fair value of stock options granted
Granted, Weighted Average Exercise Price per Share
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Lessee, Operating Lease, Liability, to be Paid, Year Three
2026
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total
Less: accumulated depreciation
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Initial Term Loan [Member]
Initial Term Loan [Member]
Miscellaneous receivables
Miscellaneous Receivables
Miscellaneous receivables.
Schedule of Available-for-sale Securities [Line Items]
Debt Securities, Available-for-Sale [Line Items]
Shareholders Equity And Stock Based Compensation [Abstract]
Shareholders equity and stock-based compensation.
Percentage of pre-launch inventory capitalized of aggregate inventory balance
Percentage Of Pre Launch Inventory Capitalized Of Aggregate Inventory Balance
Percentage of pre-launch inventory capitalized of aggregate inventory balance.
Research and Development Arrangement, Contract to Perform for Others, Type
Research and Development Arrangement, Contract to Perform for Others, Type [Domain]
Percentage increases on each anniversary of rent commencement date 2028
Percentage Increases On Anniversary Of Rent Commencement Date Option Two
Percentage increases on anniversary of rent commencement date option two.
Short term investments maturity
Short Term Investments Maximum Maturity Period
Short term investments maximum maturity period.
Entity Address, Address Line One
Entity Address, Address Line One
Series H [Member]
Series H Preferred Stock [Member]
Transfers of assets out of level 3
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3
Fair Value Hierarchy and NAV
Fair Value Hierarchy and NAV [Axis]
Earnings Per Share [Abstract]
Income Taxes
Income Tax, Policy [Policy Text Block]
Loss Contingency Accrual, Beginning Balance
Loss Contingency Accrual, Ending Balance
Loss Contingency Accrual
Litigation settlement amount
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]
Supplemental Cash Flow Information [Abstract]
Supplemental cash flow information:
Foreign Currency Translation
Foreign Currency Transactions and Translations Policy [Policy Text Block]
Non-cash interest expense related to drug product revenue
Non-cash interest expense related to drug product revenue
Gross proceeds received from sale of revenue
Gross proceeds received from sale of revenue.
Balance Sheet Location
Statement of Financial Position Location, Balance [Axis]
Investment Type [Axis]
Total operating lease right-of-use assets
Operating lease right-of-use assets, net
Operating lease right-of-use assets
Operating Lease, Right-of-Use Asset
Less: Interest
Finance Lease, Liability, Undiscounted Excess Amount
Available for sale securities in continual unrealized loss position, estimated fair value
Available for sale securities in continual unrealized loss position, estimated fair value
Debt Securities, Available-for-Sale, Unrealized Loss Position
Subtotal
Deferred Tax Assets, Gross
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]
Purchases of available-for-sale securities
Payments to Acquire Debt Securities, Available-for-Sale
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total
Change in unrealized gain or loss on investments
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax
Prepayment amount of 2024 to 2030
Prepayment amount
Prepayment amount.
Disposal Group, Including Discontinued Operation, Revenue
Product revenue, net
Recognized as Revenue (Discontinued Operations)
Commercial milestone
Commercial Milestone
Commercial milestone.
Restricted time deposits
Restricted Time Deposits Noncurrent
Restricted time deposits noncurrent.
Repayments of Senior Debt
Repayments of Senior Debt, Total
Repayments of senior secured term loan facilities
Document Type
Document Type
Total shares of common stock reserved
Common Stock Shares Reserved
Common stock shares reserved.
Income Taxes Paid, Net
Income Taxes Paid, Net, Total
Cash payment for income taxes
Collaborative Arrangement and Arrangement Other than Collaborative
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Entity Central Index Key
Entity Central Index Key
Reduction to nonredeemable noncontrolling interests
Reduction To Nonredeemable Noncontrolling Interests
Reduction to nonredeemable noncontrolling interests.
2014 Equity Incentive Plan
Two Thousand And Fourteen Equity Incentive Plan [Member]
Two thousand and fourteen equity incentive plan.
Disposal percentage
Discontinued operations disposal percentage
Discontinued operations disposal percentage.
Disposal Group, Including Discontinued Operation, Assets [Abstract]
Assets
Investments, Debt and Equity Securities [Abstract]
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]
Valuation Approach and Technique
Valuation Approach and Technique [Axis]
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Net decrease in cash and cash equivalents
Subsequent Event Type [Domain]
Beijing Kangda Yongfu Pharmaceutical Co., LTD [Member]
Beijing Kangda Yongfu Pharmaceutical Co L T D [Member]
Beijing Kangda Yongfu Pharmaceutical Co., LTD.
Anti-dilutive securities excluded from computation of net loss per share
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
2026
Revenue Payment Cap Amount Due In Year Four
Revenue payment cap amount due in year four.
Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent
Other assets
Variable consideration related to co-development billings
Variable Consideration Payment Received Related To Co Development Billings
Variable consideration payment received related to co-development billings.
Impairment of long-lived assets
Impairment of Long-Lived Assets to be Disposed of
Impairment of property and equipment
Common stock, par value
Common Stock, Par or Stated Value Per Share
Money market funds
Money Market Funds, at Carrying Value
Accounting Standards Update
Accounting Standards Update [Domain]
Cash Provided by (Used in) Continuing Operation
Net Cash Provided by (Used in) Continuing Operations, Total
Cash and cash equivalents of continuing operations
Proceeds from sale of future revenues, gross
Gross Proceeds From Sale Of Future Revenues
Gross proceeds from sale of future revenues.
Outstanding, Weighted Average Remaining Contractual Life
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term
Expected volatility, maximum
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
Amortized Cost
Debt Securities, Available-for-Sale, Amortized Cost
Components of Deferred Tax Assets and Liabilities [Abstract]
Estimated Fair Value
Investments
Total investments
Debt Securities, Available-for-Sale
Contract With Customer Liability [Table]
Contract With Customer Liability [Table]
Contract With Customer Liability [Table]
Gain (Loss) on Termination of Lease
Gain on lease termination
U.S./RoW [Member]
U.S./RoW [Member]
United States And Rest Of World [Member]
United states and rest of world.
Document Financial Statement Error Correction [Flag]
Beijing Economic-Technological Development Area [Member]
Beijing Economic Technological Development Area [Member]
Beijing economic-technological development area.
Disallowed interest, Amount
Income Tax Reconciliation Nondeductible Expense Disallowed Interest
Income tax reconciliation nondeductible expense disallowed interest.
Debt Disclosure [Abstract]
Upfront, non-contingent, non-refundable and time-based payments
Proceeds From Upfront Non Contingent Non Refundable And Time Based Payments
Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration.
AstraZeneca U.S./RoW Agreement [Member]
AstraZeneca U.S./RoW Agreement [Member]
AstraZeneca U.S./RoW agreement member.
Disposal Group, Including Discontinued Operation, Cash Payable at Closing Subject to Holdbacks
Disposal group, including discontinued operation, cash payable at closing subject to holdbacks.
Discontinued operation cash payable at closing subject to holdbacks
Currency translation adjustment
Translation Adjustment Functional to Reporting Currency, Net of Tax, Ending Balance
Translation Adjustment Functional to Reporting Currency, Net of Tax, Beginning Balance
Translation Adjustment Functional to Reporting Currency, Net of Tax
Balance Presented NetAgainst Contract Asset
Contract with customer liability net of balance presented against contract asset
Contract with customer liability net of balance presented against contract asset.
Repayments of Related Party Debt
Payment to related parties
Total accrued and other current liabilities
Accrued Liabilities, Current
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Percentage of excise tax on stock buyback
Percentage Of Excise Tax On Stock Buyback
Percentage of excise tax on stock buyback.
Ownership [Domain]
Series F [Member]
Series F Preferred Stock [Member]
Current Fiscal Year End Date
Current Fiscal Year End Date
Schedule of Long-Term Debt Instruments [Table]
Debt Instrument [Table]
Cash paid to non-controlling interest
Payments to Noncontrolling Interests
Schedule of Other Long-term Liabilities
Other Noncurrent Liabilities [Table Text Block]
Schedule of Long Lived Assets by Geographic Area
Long-Lived Assets by Geographic Areas [Table Text Block]
Restricted Cash and Cash Equivalents, Noncurrent, Total
Restricted time deposits
Restricted Cash and Cash Equivalent, Noncurrent
Laboratory Equipment [Member]
Laboratory Equipment [Member]
Laboratory equipment.
CALIFORNIA
California [Member]
Percentage of revenue interest on global net sales
Percentage Of Revenue Interest On Global Net Sales
Percentage of revenue interest on global net sales.
Entity Address, State or Province
Entity Address, State or Province
RSUs outstanding
Unvested, Shares, Beginning Balance
Unvested, Shares, Ending Balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Co-development, information sharing & committee services [Member]
Co Development Information Sharing And Committee Services [Member]
Co development information sharing and committee services.
Schedule of Maturities of Finance and Operating Leases Liabilities
Schedule Of Maturities Of Finance And Operating Leases Liabilities Table [Text Block]
Schedule of maturities of finance and operating leases liabilities.
Deferred tax liabilities fixed assets.
Fixed assets
Deferred Tax Liabilities Fixed Assets
Investment, Name [Domain]
Preferred Stock, Shares Outstanding, Ending Balance
Preferred Stock, Shares Outstanding, Beginning Balance
Preferred stock, shares outstanding
Preferred Stock, Shares Outstanding
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive income (loss)
Gross Unrealized Holding Gains
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Research and Development Expenses
Research and Development Expense, Policy [Policy Text Block]
Number of common stock reserved for issuance
Shares reserved for future ESPP offering
Common Stock, Capital Shares Reserved for Future Issuance
Commitments And Contingencies [Line Items]
Commitments And Contingencies [Line Items]
Commitments and contingencies.
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]
Discontinued Operations and Divestiture
Geographical
Geographical [Axis]
Accounts receivable from related parties
Increase (Decrease) in Accounts Receivable, Related Parties
Recognized as Revenue
Contract with Customer, Liability, Revenue Recognized
Royalty revenue recognized as drug product revenue
Milestone Payments [Member]
Milestone payments [Member]
Milestone payments.
Discontinued Operations, Policy [Policy Text Block]
Discontinued Operations
Percentage of outstanding shares owned
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage
Discontinued operation consideration
Interest expense recognized
Noncash Interest Expense Related To Sale Of Future Revenue
Noncash interest expense related to sale of future revenue.
Percentage of Accounts Receivable [Member]
Accounts Receivable [Member]
Accounts Receivable [Member]
Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance
Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance
Stockholders' Equity Attributable to Noncontrolling Interest, Total
Non-controlling interests
Equity, Attributable to Noncontrolling Interest
Disposal Group Including Discontinued Operation Additional Payment Following Final Net Cash Adjustments after Closing
Disposal group including discontinued operation additional payment following final net cash adjustments after closing.
Disposal group including discontinued operation additional payment following final net cash adjustments after closing
Office Spaces
Office Spaces [Member]
Office spaces.
Net operating losses not benefitted
Effective Income Tax Rate Reconciliation Net Operating Losses Not Benefitted
Effective income tax rate reconciliation net operating losses not benefitted.
State tax, net of federal benefit, Amount
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount
License Revenue [Member]
License [Member]
License [Member]
Schedule of Recorded Stock-Based Compensation Expense
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount
Other, Amount
Beyond 2027
Finance Lease, Liability, to be Paid, after Year Five
Comprehensive Income (Loss)
Comprehensive Income, Policy [Policy Text Block]
Schedule of Significant Components of Deferred Tax Assets
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]
Schedule of Customer Concentration by Collaboration Partners
Other comprehensive income (loss):
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Income (Loss) from Continuing Operations, Per Basic Share
Loss from continuing operations per share - basic
Subsequent Event [Member]
Subsequent event [Member]
Redemption Of Fractional Shares Due To Reverse Stock Split Value
Redemption of fractional shares due to reverse stock split value.
Redemption of fractional shares due to reverse stock split
Equity Method Investment, Nonconsolidated Investee [Domain]
Equity Method Investment, Nonconsolidated Investee
Property, Plant and Equipment [Abstract]
Billed Contracts Receivable
Other assets
Other Assets, Noncurrent
Interest income and other income (expenses), net
Interest income and other income (expenses), net
Disposal Group Including Discontinued Operation Interest Income And Other Expenses Net
Disposal group including discontinued operation interest income and other expenses net.
Lessee, finance lease, existence of option to extend
Lessee, Finance Lease, Existence of Option to Extend [true false]
Antidilutive Securities
Antidilutive Securities [Axis]
2014 ESPP [Member]
Two Thousand And Fourteen Employee Stock Purchase Plan [Member]
Two thousand and fourteen employee stock purchase plan.
NovaQuest [Member]
NovaQuest Capital Management [Member]
NovaQuest Capital Management.
NovaQuest Capital Management [Member]
Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]
Reconciliation of cash and cash equivalents to the consolidated balance sheets:
Expired, Shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period
Percentage of vesting rights
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage
Vested and expected to vest, Aggregate Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Interest Expense, Debt, Total
Interest Expense, Debt
Interest expense
Product Development Obligations
Product Development Obligations Disclosure [Text Block]
Product development obligation disclosure.
State [Member]
State and Local Jurisdiction [Member]
Lessee, finance lease, option to extend
Lessee, Finance Lease, Option to Extend
Accumulated Other Comprehensive Loss [Member]
AOCI Attributable to Parent [Member]
Payment of Senior Secured Term Loan Facilities Pay-off Premium and Fees
Payment of senior secured term loan facilities pay-off premium and fees.
Payment of senior secured term loan facilities pay-off premium and fees
Adjustments to additional paid in capital
Adjustments To Additional Paid In Capital
Adjustments to additional paid in capital.
Finite-Lived Intangible Assets, Major Class Name
Finite-Lived Intangible Assets, Major Class Name [Domain]
Deferred revenue current to related party
Due To Related Parties Deferred Revenue Current
Due to related parties deferred revenue current.
Drug product revenue from a related party
Drug Product Revenue From Related Party
Drug product revenue from related party.
Deferred Approval Milestone [Member]
Deferred Approval Milestone [Member]
Deferred approval milestone.
Disposal Group, Including Discontinued Operation, Assets, Noncurrent
Total long-term assets held for sale
Long-term assets held for sale
AstraZenecaAB [Member]
Astra Zeneca A B [Member]
AstraZeneca AB.
Purchase consideration
Business Combination, Consideration Transferred, Total
Business Combination, Consideration Transferred
Preferred Stock, Value, Issued
Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at December 31, 2025 and 2024
Kyntra Bio [Member]
Kyntra Bio [Member]
Kyntra Bio.
Amortization of right-of-use assets
Finance Lease, Right-of-Use Asset, Amortization Continuing Operations
Finance lease, right-of-use asset, amortization continuing operations.
Maximum payment cap amount
Maximum payment cap amount.
Disposal Groups, Including Discontinued Operations [Table Text Block]
Schedule of Financial Results, Carrying Value of Assets and Liabilities and Significant Non-Cash Items and Capital Expenditures of Discontinued Operations
Selling, General and Administrative Expense, Total
Selling, general and administrative
Selling, General and Administrative Expense
Maturity date
Debt Instrument, Maturity Date
Due to related parties, noncurrent
Other liabilities noncurrent due to related parties.
Other Liabilities Noncurrent Due to Related Parties
Minimum [Member]
Minimum [Member]
Granted, Weighted Average Fair value at Grant
Weighted-average fair value of awards granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Financial Instrument
Financial Instrument [Axis]
Current assets:
Assets, Current [Abstract]
Summary of Equity Method Investment
Equity Method Investments [Table Text Block]
Effective Income Tax Rate Reconciliation, GILTI, Amount
Global intangible low-taxed income, Amount
Total lease assets
Finance Lease And Operating Lease Assets
Finance lease and operating lease assets.
Astellas and AstraZeneca [Member]
Astellas And Astra Zeneca [Member]
Astellas and AstraZeneca.
Collaboration Arrangements and Revenues
Collaborative Arrangement And Revenues Policy [Text Block]
Collaborative arrangement and revenues.
Level 3 [Member]
Fair Value, Inputs, Level 3 [Member]
Astellas Agreement [Member]
Astellas agreement.
Astellas Agreement [Member]
Segment Reporting [Abstract]
Currency Translation
Equity Method Investment Increase Decrease From Currency Translation
Equity method investment increase (decrease) from currency translation.
Percentage of ownership changes
Experience Historical Ownership Changes
Experience historical ownership changes.
Tax Period
Tax Period [Domain]
Manufacture and Supply of Pamrevlumab
Manufacture and supply of pamrevlumab.
Manufacture And Supply Of Pamrevlumab [Member]
Commitments And Contingencies [Table]
Commitments And Contingencies [Table]
Commitments and contingencies.
Fair Values of Financial Assets Measured on Recurring Basis
Fair Value, Assets Measured on Recurring Basis [Table Text Block]
Current liabilities:
Liabilities, Current [Abstract]
Operating lease right-of-use assets
Increase Decrease In Operating Lease Right Of Use Assets
Increase (decrease) in operating lease right-of-use assets.
Product [Member]
Product Revenue, Net [Member]
Product [Member]
Provision for co-development services
Provision For Co Development Services
Provision for co-development services.
U.S./RoW and China [Member]
United States And Rest Of World And China [Member]
United states and rest of world and china.
Accrued interest, unrecognized tax benefits
Unrecognized Tax Benefits, Interest on Income Taxes Accrued
Increase Decrease In Accrued Interest Expense Related To Sale Of Future Revenues
Increase (decrease) in accrued interest expense related to sale of future revenues
Accrued interest expense related to sale of future revenues
Related Party Transactions [Abstract]
Commercial sales milestone
Commercial Sales Milestone
Represents the amount of milestone payments related to commercial sales under the collaborative agreement.
Balance, Shares
Balance, Shares
Shares, Outstanding
Summary of Available for Sale Securities in Unrealized Loss Position, Fair Value and Gross Unrealized Loss By Length of Time Security in Continual Unrealized Loss Position
Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]
Sublease income
Sublease Income
Accounts Receivable, after Allowance for Credit Loss, Current
Accounts receivable, net ($6,079 and $12,088 from related parties)
Accounts receivable from related parties
Accounts receivable, net
Impact of change in accounting principle upon adoption of ASU 2018-02 [Member]
Impact Of Change In Accounting Principle Upon Adoption Of A S U201802 [Member]
Impact of change in accounting principle upon adoption of ASU 2018-02.
Received from sale of revenue
Received From Sale of Revenue
Received from sale of revenue.
Liability Related To Sale Of Revenue Current
Liability related to sale of revenue current.
Less: Current portion classified to accrued and other current liabilities
Less: Current portion classified to accrued and other current liabilities
Contract assets
Unbilled contract asset
Prepaid Supplies
Disposal Group, Including Discontinued Operation, Liabilities [Abstract]
Liabilities
Commitments and Contingencies
Commitments and Contingencies (Note 11)
Leases
Lessee, Leases [Policy Text Block]
SEC Schedule, 12-09, Valuation Allowances and Reserves
SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]
Unvested, Weighted Average Fair value at Grant, Ending Balance
Unvested, Weighted Average Fair value at Grant, Beginning Balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Equity and Stock-based Compensation
Shareholders' Equity and Share-Based Payments [Text Block]
Total Consideration
Cash Consideration Received Under Collaboration Agreement
The total cash consideration received under a collaboration agreement that has been allocated to the different significant units of accounting and includes the portion that has been deferred for revenue recognition.
Cash Consideration Received Under Collaboration Agreement
Total Consideration
Operating Lease, Liability, Total
Present value of lease liabilities
Operating lease liability
Operating Lease, Liability
Auditor Firm ID
Auditor Firm ID
Reverse stock split
Stockholders' Equity, Reverse Stock Split
Cash dividend percentage
Preferred Stock, Dividend Rate, Percentage
Description of payment term
Revenue, Performance Obligation, Description of Payment Terms
Percentage of Accounts Receivable [Member]
Concentration Risk Benchmark
Concentration Risk Benchmark [Axis]
Category of Item Purchased
Category of Item Purchased [Axis]
2023
Revenue Payment Cap Amount Due Next Twelve Months
Revenue payment cap amount due next twelve months.
Disposal group including discontinued operation interest and other net.
Disposal Group Including Discontinued Operation Interest And Other Net [Abstract]
Interest and other, net
Payment to options exercised
Payment to Options Exercised
Payment to options exercised
Finance lease liabilities, current
Finance lease liabilities
Finance lease liabilities, current
Finance Lease, Liability, Current
Lessee Lease Description [Table]
Lessee, Lease, Description [Table]
Finance leases
Finance Lease, Weighted Average Discount Rate, Percent
HiFiBiO Agreement [Member]
Hi Fi Bi O Agreements [Member]
HiFiBiO Agreement.
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent
Change in valuation allowance
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total
Effect of exchange rate change on cash and cash equivalents
Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
Net loss
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Net loss
Net income (loss)
Lease Contractual Term
Lease Contractual Term [Domain]
Disposal Group, Including Discontinued Operation, Liabilities, Current
Total current liabilities held for sale
Current liabilities held for sale
Asset acquisition policy.
Asset Acquisition Policy [Policy Text Block]
Asset Acquisition
Disposal Group, Including Discontinued Operation, Operating Expense
Total operating costs and expenses
Total operating costs and expenses
Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount
Stock based compensation, Amount
Geographic Distribution
Geographic Distribution [Axis]
Senior secured term loan facilities, current
Secured Debt, Current
Long-Term Debt, Type [Domain]
Regulatory Milestone [Member]
Regulatory Milestones [Member]
Regulatory milestone.
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]
Basic
Weighted Average Number of Shares Outstanding, Basic
Weighted Average Number of Shares Outstanding, Basic, Total
Acquisition And Variable Interest Entity [Abstract]
Acquisition and variable interest entity abstract.
Schedule of Revenue by Geographic Area
Revenue from External Customers by Geographic Areas [Table Text Block]
China performance obligation [Member]
China Performance Obligation [Member]
China performance obligation.
Capitalized research and development expenses
Deferred Tax AssetsTax Capitalized Research And Development Expenses
Deferred tax assets tax capitalized research and development expenses.
Total intrinsic value of options exercised
Exercisable, Aggregate Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value
Income Taxes [Table]
Income taxes.
Income Taxes [Table]
Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent
Stock based compensation
Schedule of Reconciliation Between Statutory Federal Income Tax Rate and Effective Tax Rate
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Available for sale securities in continual unrealized loss position, 12 months or more, gross unrealized holding losses
Available for sale securities in continual unrealized loss position, 12 months or more, gross unrealized holding losses
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss
Income before income taxes
Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax
Income before income taxes
Long-Lived Tangible Asset
Long-Lived Tangible Asset [Domain]
Accrued Interest
Interest Payable
Schedule Of Leases [Table]
Schedule Of Leases [Table]
Schedule of leases.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]
Astellas Europe Agreement [Member]
Astellas Europe Agreement [Member]
Astellas Europe Agreement.
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]
Subsequent Events [Text Block]
Subsequent Event
Tax credits
Effective Income Tax Rate Reconciliation, Tax Credit, Percent
Effective Income Tax Rate Reconciliation, Tax Credit, Percent, Total
Long-Term Debt
Term loan
Senior secured term loan facilities, ending balance
Senior secured term loan facilities, ending balance
Related Party Transactions
Related Party Transactions Disclosure [Text Block]
Cash
Cash
Interest expense recognized
Non-cash interest expense related to sale of future revenues
Non Cash Interest Expense Related To Sale Of Future Revenues
Non cash interest expense related to sale of future revenues.
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total
Stock-based compensation
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
Variable Rate
Variable Rate [Domain]
Disposal group, including discontinued operation, consideration transaction costs and fees
Disposal group, including discontinued operation, consideration transaction costs and fees.
Discontinued operation consideration transaction costs and fees
Foreign exchange rate differential
Unrecognized Tax Benefits, Increase (Decrease) Resulting from Foreign Currency Translation
Unrecognized tax benefits, increase (decrease) resulting from foreign currency translation.
Change in valuation allowance, Amount
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount
Stockholders' Equity Attributable to Parent, Ending Balance
Stockholders' Equity Attributable to Parent, Beginning Balance
Equity, Attributable to Parent
Total stockholders' deficit attributable to Kyntra Bio
Preferred stock, par value
Preferred Stock, Par or Stated Value Per Share
Disposal group not discontinued operation gain loss on disposal statement of income extensible list not disclosed flag.
Disposal group not discontinued operation gain loss on disposal statement of income extensible list not disclosed flag
Share Purchase Agreement [Member]
Share purchase agreement.
Basis of Presentation
Basis of Accounting, Policy [Policy Text Block]
Product development obligations
Product Development Costs
Product Development Costs
Corporate alternative minimum tax percentage
Corporate Alternative Minimum Tax Percentage
Corporate alternative minimum tax percentage.
Statement of Stockholders' Equity [Abstract]
Series C [Member]
Series C Preferred Stock [Member]
Equity method investment in unconsolidated variable interest entity
Beginning balance
Ending balance
Equity Method Investments
Equity method investments
Valuation Approach and Technique
Valuation Approach and Technique [Domain]
Series A [Member]
Series A Preferred Stock [Member]
Series A Preferred Shares [Member]
Use of Estimates
Use of Estimates, Policy [Policy Text Block]
Credit Losses – Available-For-Sale Debt Securities
Credit Loss, Financial Instrument [Policy Text Block]
Reverse Stock Split [Member]
Reverse Stock Split [Member]
Valuation Allowances for Rebates, Discounts and Adjustments [Member]
Valuation Allowances for Rebates, Discounts and Adjustments [Member]
Percentage increases on each anniversary of rent commencement date 2023
Percentage Increases On Each Anniversary Of Rent Commencement Date
Percentage increases on each anniversary of rent commencement date.
Collaborative Arrangement [Member]
Collaborative Arrangement [Member]
Product Revenue, Net
Product Revenue Policy Policy [Text Block]
Product revenue policy.
Leasehold improvements [Member]
Leasehold Improvements [Member]
Entity Address, Address Line Two
Fair Value Measurements
Fair Value Disclosures [Text Block]
Drug Product Revenue Policy [Text Block]
Drug product revenue.
Drug Product Revenue, Net
Earliest Tax Year [Member]
Earliest Tax Year [Member]
Accrued Liabilities Paid
Accrued liabilities paid.
Accrued liabilities paid
Purchase of common stock shares at discount
Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date
Less: Transaction costs
Transaction Costs Related To Sale Of Future Revenues
Transaction costs related to sale of future revenues.
Interest Paid Related to Sale of Future Revenues
Interest paid related to sale of future revenues.
Interest paid
Development and regulatory approval milestones
Development And Regulatory Approval Milestones
Represents the potential amount of milestone payments related to development and regulatory approval under the collaborative agreement.
United States [Member]
U.S. [Member]
UNITED STATES
Product Information [Line Items]
Noncontrolling Interests [Member]
Noncontrolling Interest [Member]
Liability Related to Sale of Future Revenues
Liability Related To Sale of Future Revenue [Text Block]
Liability related to sale of future revenue.
Schedule of Accrued and Other Current Liabilities
Schedule of Accrued Liabilities [Table Text Block]
Debt Instrument, Name [Domain]
Other current assets
Other Assets, Current
Measurement Input Discount Rate [Member]
Measurement Input, Discount Rate [Member]
Accrued Liabilities and Other Liabilities
Accrued and other current liabilities
Income (Loss) from Equity Method Investments
Share of Net Income
Investment income
Effective Income Tax Rate Reconciliation Discontinued Operations
Effective income tax rate reconciliation discontinued operations.
Discontinued operations
Schedule of Reconciliation of the Beginning and Ending Amounts of Unrecognized Income Tax Benefits
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]
Income from discontinued operations per share - basic
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share, Total
Description of discontinued operations
Disposal Group, Including Discontinued Operation, Description and Timing of Disposal
IPR&D Asset [Member]
In Process Research and Development [Member]
Plan Name
Plan Name [Domain]
Disposal Group Including Discontinued Operation Equity Method Investment In Unconsolidated Variable Interest Entity
Disposal Group Including Discontinued Operation Equity Method Investment In Unconsolidated Variable Interest Entity.
Equity method investment in unconsolidated variable interest entity
Amount constrained related to drug product shipment
Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price
Increase (Decrease) in Other Operating Assets, Total
Other assets
Increase (Decrease) in Other Operating Assets
Interest Expense, Total
Interest expense
Interest Expense, Operating and Nonoperating
Summary of Finance and Operating Lease Right of Use Assets by Geographical Location
Summary Of Finance And Operating Lease Right Of Use Assets By Geographical Location Table [Text Block]
Summary of Finance and Operating Lease Right of Use Assets by Geographical Location.
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Entity
Entity [Domain]
Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]
Stock Option Awards [Member]
Stock Option Awards [Member]
Stock option awards.
Equity Method Investment, Ownership Percentage
Ownership percentage
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]
Accrued restructuring charges.
Accrued Restructuring Charges
Accrued restructuring charges
State
Current State and Local Tax Expense (Benefit)
Shares issued from stock plans, net of payroll taxes paid, Shares
Shares Issued From Stock Plans Net Of Payroll Taxes Paid Shares
Shares issued from stock plans net of payroll taxes paid shares.
The Company
Business Description and Basis of Presentation [Text Block]
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]
Finance Lease, Liability, to be Paid, Year One
2024
Option vesting term
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights
Warrants to purchase common stock outstanding
Class of Warrant or Right, Outstanding
Tax Period
Tax Period [Axis]
RSUs released and issued net of shares withheld for taxes
Restricted Stock, Shares Issued Net of Shares for Tax Withholdings
Operating Leases
Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]
Potential milestone payments
Potential Milestones
Represents the total potential amount of milestone payments related to development, regulatory approval and commercial sales under the collaborative agreement.
Related Party
Related and Nonrelated Parties [Axis]
Other, Amount
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount
Eluminex [Member]
Eluminex Collaboration Agreement [Member]
Eluminex collaboration agreement.
Foreign net operating loss [Member]
Foreign Tax Jurisdiction [Member]
Shorenstein Properties LLC [Member]
Shorenstein Properties L L C [Member]
Shorenstein properties LLC.
Property and Equipment
Property, Plant and Equipment, Policy [Policy Text Block]
Nonredeemable non-controlling interests
Nonredeemable Noncontrolling Interest
Disposal Group Name [Domain]
Disposal Group Including Discontinued Operation Revenue [Abstract]
Disposal group including discontinued operation revenue.
Revenue:
Other Risks and Uncertainties
Other Risks And Uncertainties Policy [Text Block]
Other Risks and Uncertainties.
Entity Address, City or Town
Entity Address, City or Town
Loss Contingency, Civil Penalty Payment
Loss contingency, civil penalty payment.
Civil penalty payment
Number of common stock repurchased
Stock Repurchased During Period, Shares
Number of reportable segment
Number of Reportable Segments
Security Exchange Name
Security Exchange Name
Europe [Member]
Europe [Member]
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]
Redeemable Noncontrolling Interest, Equity, Carrying Amount, Total
Redeemable Noncontrolling Interest, Equity, Carrying Amount
Redeemable non-controlling interests
Upfront, non-contingent and time-based payments received
Proceeds From Upfront Non Contingent And Time Based Payments
Represents the amount of fixed and determinable non-contingent upfront payments included under the collaborative agreement as arrangement consideration.
Amount received
Principal of senior secured term loan facilities
Initial term loan amount
Other
Effective Income Tax Rate Reconciliation, Other Adjustments, Percent
Property, Plant and Equipment, Gross, Ending Balance
Property, Plant and Equipment, Gross, Beginning Balance
Property, Plant and Equipment, Gross, Total
Property and equipment, gross
Property, Plant and Equipment, Gross
Fair value of the acquired in process research and development assets.
Fair value of the acquired in process research and development assets
Fair value of the acquired IPR&D assets
Counterparty Name [Axis]
Loss before provision for income taxes
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Convertible promissory note [Member]
Convertible promissory note.
Convertible promissory note [Member]
Vested and expected to vest, Shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Concentration Risk Type
Concentration Risk Type [Domain]
Finance Lease, Liability, to be Paid, Year Five
2028
PRSUs [Member]
Performance Based Restricted Stock Awards [Member]
Performance based restricted stock awards.
Accrued Liabilities
Accrued Liabilities [Member]
Measurement Input Type
Measurement Input Type [Domain]
Antidilutive Securities, Name
Antidilutive Securities, Name [Domain]
FibroGen Europe [Member]
Fibrogen Europe Oy [Member]
Fibro Gen Europe Oy.
Foreign net operating losses not benefitted
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent
Foreign Rate Differential
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share, Total
Income from discontinued operations per share - diluted
Total inventory
Total inventories
Inventories
Inventory, Net
Summary of RSU,PRSU and TSR Awards
Schedule Of ShareBased Compensation Restricted Stock Units Perfomance Based Restricted Stock And Total Shareholders Return Award Activity [TableTextBlock]
Schedule of shareBased compensation restricted stock units perfomance based restricted stock and total shareholders return award activity.
Future revenue granted
Future revenue granted.
Collaboration services and other revenue from a related party
Collaboration Services And Other Revenue
Revenue recognized from co-development services, manufacturing of clinical supplies, committee services and information services and other revenue.
Interest payments
Interest Paid, Excluding Capitalized Interest, Operating Activity
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]
Statistical Measurement
Statistical Measurement [Domain]
Payment Cap Date on or before December 31, 2028 [Member]
Payment cap date on or before December thirty one two thousand twenty eight [Member]
Payment cap date on or before December thirty one two thousand twenty eight.
Total current assets
Assets, Current
Total stock-based compensation expense
Share-Based Payment Arrangement, Expense
Document Period End Date
Document Period End Date
Collaborative Arrangement And Revenues Disclosure [Text Block]
Collaborative arrangement and revenues.
Collaboration Agreements, License Agreement and Revenues
Disposal Group Including Discontinued Operation Operating Lease Liability Noncurrent
Disposal group including discontinued operation operating lease liability noncurrent.
Operating lease liabilities, non-current
AstraZeneca [Member]
AstraZeneca Agreements [Member]
Astra Zeneca Agreements [Member]
Astra Zeneca agreements.
Fair Value Hierarchy and NAV
Fair Value Hierarchy and NAV [Domain]
ICFR Auditor Attestation Flag
ICFR Auditor Attestation Flag
Exercisable, Shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Effective Income Tax Rate Reconciliation Worldwide Changes In Unrecognized Tax Benefits Percentage
Effective income tax rate reconciliation worldwide changes in unrecognized tax benefits percentage.
Worldwide changes in unrecognized tax benefits
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]
Holdback consideration receivable related to divestiture
Holdback consideration receivable related to divestiture
Holdback consideration receivable related to divestiture
Rent increase commencement year second option
Scheduled Rent Commencement Year Option Two
Scheduled rent commencement year option two.
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]
Operating loss carryforwards expiration year
Operating Loss Carryforwards Expiration Year
Operating loss carryforwards expiration year.
Statement of Financial Position [Abstract]
RSUs [Member]
Restricted Stock Unit [Member]
Restricted Stock Units (RSUs) [Member]
Cumulative Effect, Period of Adoption, Adjustment [Member]
Cumulative Effect, Period of Adoption, Adjustment [Member]
Accrued restructuring charge current.
Accrued Restructuring Charge Current
Accrued restructuring charge
Revenue Recognition
Revenue [Policy Text Block]
FibroGen International [Member]
FibroGen international.
Preclinical and clinical trial accruals
Accrued Preclinical And Clinical Trial Current
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to pre-clinical and clinical trial activities, including those performed by third parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Lessee, Operating Lease, Existence of Option to Terminate [true false]
Cash received for sale of discontinued operation
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]
Antidilutive Security, Excluded EPS Calculation [Table]
Class of Stock
Class of Stock [Axis]
Deferred Tax Liabilities, Net, Total
Net deferred tax liabilities
Deferred Tax Liabilities, Net
Closing of Divestiture of FibroGen International [Member]
Closing of Divestiture of FibroGen International, member.
Other Liabilities, Noncurrent [Abstract]
Senior secured term loan facilities.
Senior Secured Term Loan Facilities [Member]
Total current
Current Income Tax Expense (Benefit)
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Effective annual interest rate related to sale of future revenues
Effective Annual Interest Rate Related To Sale Of Future Revenues
Effective Annual Interest Rate Related To Sale Of Future Revenues
Finance Leases
Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]
Valuation And Qualifying Accounts Disclosure [Line Items]
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Total liabilities
Liabilities
Operating costs and expenses:
Operating Costs and Expenses [Abstract]
Proceeds from Divestiture of Businesses, Net of Cash Divested
Proceeds from Divestiture of Businesses, Net of Cash Divested, Total
Proceeds from divestiture, net of cash transferred
Financial Instruments
Financial Instruments [Domain]
Lease Amendment [Member]
Lease Amendment [Member]
Lease amendment.
Net cash held
Cash and cash equivalents
Cash and cash equivalents included in assets held for sale
Upfront payment
Collaborative Arrangement Aggregate Consideration For Milestone And Upfront Payments
Collaborative arrangement aggregate consideration for milestone and upfront payments.
Aggregate consideration received for milestone and upfront payments
Deferred revenue from related parties
Increase (Decrease) in Deferred Revenue
Contract with Customer Liability [Line Items]
Contract With Customer Liability [Line Items]
Contract with customer liability.
ATM Program [Member]
ATM Program.
Other-than-temporary impairment loss
Other-than-temporary Impairment Loss, Debt Securities, Available-for-Sale
Minority Shareholders [Member]
Majority Shareholder [Member]
Total dividends distributed
Dividends
Dividends, Total
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount
Foreign Rate Differential, Amount
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total
Reserves and accruals
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals
Lessee, Operating Lease, Liability, to be Paid, Year Two
2025
Disposal Groups, Including Discontinued Operations [Table]
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]
Amortization of right-of-use assets
Amortization of finance lease right-of-use assets
Finance Lease, Right-of-Use Asset, Amortization
Variable Rate
Variable Rate [Axis]
Prepaid Expense and Other Assets, Current [Abstract]
Balance at Beginning of Year
Balance at End of Year
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount
Available for sale securities in continual unrealized loss position, less than 12 months, gross unrealized holding losses
Available for sale securities in continual unrealized loss position, less than 12 months, gross unrealized holding losses
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss
Diluted
Weighted Average Number of Shares Outstanding, Diluted
Weighted Average Number of Shares Outstanding, Diluted, Total
Entity File Number
Entity File Number
Payment Cap Date after January 1, 2030 [Member]
Payment cap date after January one two thousand thirty [Member]
Payment cap date after January one two thousand thirty.
Unrealized gain (loss) on investments, net of tax effect
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax
Optional rights to extend lease
Number Of Optional Rights To Extend Lease
Number of optional rights to extend lease.
Lessee, finance lease, expiration period
Lessee Finance Lease Expiration Period
Lessee, finance lease, expiration period.
Cover [Abstract]
Cover
Fortis Therapeutics [Member]
Fortis Therapeutics.
Fortis Therapeutics [Member]
Deferred:
Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]
Expected volatility, minimum
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum
Measurement Input Type
Measurement Input Type [Axis]
Schedule of Lease Term and Discount Rate
Schedule Of Lease Term And Discount Rate Table [Text Block]
Schedule of lease term and discount rate.
Disposal Group, Including Discontinued Operation, Other Receivable
Disposal group, including discontinued operation other receivable.
Discontinued operation other receivable
Cumulative Effect, Period of Adoption
Cumulative Effect, Period of Adoption [Axis]
Prepaid expenses and other current assets
Total prepaid expenses and other current assets
Prepaid Expense and Other Assets, Current
Forfeited, Shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Agency bonds [Member]
Agency Bonds [Member]
Agency bonds.
Operating lease liabilities, non-current
Increase Decrease In Operating Lease Liabilities Non Current
Increase (decrease) in operating lease liabilities, non-current.
Investments [Domain]
Sale proceeds from common stock
Sale Of Common Stock Aggregate Offering Price Authorized
Sale of common stock aggregate offering price authorized.
Loss Contingency, Receivable, Current
Litigation settlement receivable
Insurance proceeds receivable for litigation settlement
Balance Sheet Components
Supplemental Balance Sheet Disclosures [Text Block]
Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest
Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest, Ending Balance
Debt Securities, Available-for-Sale, Allowance for Credit Loss, Excluding Accrued Interest, Beginning Balance
Available-for-sale debt securities
Accounting Policy [Line Items]
Accounting Policy [Line Items]
Accounting policy.
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest
Loss from continuing operations before income taxes
Percentage of Revenue [Member]
Revenue Benchmark [Member]
Before December 31, 2028 [Member]
Payment Period One [Member]
Payment Period One [Member]
Payment Period One [Member]
Number of operating segment
Number of Operating Segments
Sale of Stock
Sale of Stock [Domain]
Segment and Geographic Information
Segment Reporting Disclosure [Text Block]
Discount rate applied
Alternative Investment, Measurement Input
Series B [Member]
Series B Preferred Stock [Member]
Acquisition And Variable Interest Entity [Table]
Acquisition And Variable Interest Entity [Table]
Acquisition and variable interest entity table.
Disallowed interest
Effective Income Tax Rate Reconciliation, Nondeductible Expense Disallowed Interest
Effective income tax rate reconciliation nondeductible expense disallowed interest.
Litigation settlement
Litigation settlement current.
Litigation Settlement Current
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares
Shares vested
Valuation And Qualifying Accounts Disclosure [Table]
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]
Investment Income, Dividend
Dividend received
Dividend Received
Minimum percentage of shareholder's approval to call for redemption of preferred shares
Required Minimum Shareholder Percentage To Call For Redemption Of Preferred Shares
Required minimum shareholder percentage to call for redemption of preferred shares.
Falikang
Falikang [Member]
Falikang.
Disposal group, including discontinued operation, hold back amount to satisfy any indemnity claims
Disposal group, including discontinued operation, hold back amount to satisfy any indemnity claims.
Discontinued operation, hold back amount to satisfy any indemnity claims
Other
Deferred Tax Assets, Other
Current:
Current Federal, State and Local, Tax Expense (Benefit) [Abstract]
Percentage points deducted to reference rate to compute effective interest rate
Loans Receivable, Basis Spread on Variable Rate
Operating Lease, Expense
Operating lease
Gain (Loss) on Extinguishment of Debt
Gain (Loss) on Extinguishment of Debt, Total
Loss on debt extinguishments
Loss on debt extinguishments
Vested and expected to vest, Weighted Average Exercise per Share
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Nature of Operation, Product Information, Concentration of Risk [Table]
Schedule of Components of Loss Before Income Taxes
Schedule Of Income Loss Before Income Tax Domestic And Foreign Table [Text Block]
Schedule of income loss before income tax domestic and foreign.
Restructuring charge
Restructuring Charges, Total
Restructuring Charges
Restructuring plan, non-recurring charges
Property and equipment estimated useful life
Property, Plant and Equipment, Useful Life
FibroGen, Inc. [Member]
Fibro Gen Inc [Member]
FibroGen, Inc.
Investment income in unconsolidated variable interest entity
Disposal Group Including Discontinued Operation Investment Income In Unconsolidated Variable Interest Entity
Disposal group including discontinued operation investment income in unconsolidated variable interest entity.
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Profit share liability
Deferred Revenue
Deferred revenue
Gain (Loss) on Disposition of Assets
Gain (Loss) on Disposition of Assets, Total
Loss on disposal
Loss on disposal
Development revenue.
Development Revenue [Member]
Other
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent
Ownership [Axis]
Other investors.
Other Investors [Member]
FibroGen Cayman.
FibroGen Cayman [Member]
Fibro Gen Cayman [Member]
Disposal Group, Including Discontinued Operation, Consideration
Aggregate purchase price
Discontinued operation consideration
Risk-free interest rate, minimum
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
Domestic
Income (Loss) from Continuing Operations before Income Taxes, Domestic
Depreciation, Total
Depreciation
Depreciation
Depreciation expense for the continuing operations
Unrecognized compensation costs
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount
Lessee, operating lease, lease term
Lessee, Operating Lease, Term of Contract
Long-term investments
Long-Term Investments, Total
Long-Term Investments
Long-term investment
Common Stock, Shares, Outstanding, Ending Balance
Common Stock, Shares, Outstanding, Beginning Balance
Common stock outstanding
Common stock, shares outstanding
Common Stock, Shares, Outstanding
Operating lease liabilities
Operating lease liabilities, current
Operating Lease, Liability, Current
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue during period from performance obligations
Revenue, Remaining Performance Obligation, Amount
Summary of License Revenue and Development Revenue Recognized under Agreement
Contract With Customer Milestone Method Table [Text Block]
Contract with customer milestone method.
Cybersecurity Risk Management Processes Integrated [Flag]
Document Transition Report
Document Transition Report
Total net deferred tax assets
Deferred Tax Assets, Net
Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]
Short-Term Investments, Total
Short-term investments
Short-Term Investments
Accrued Liabilities, Current [Abstract]
Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent
Property and equipment, net
Research and Development Expense, Total
Research and development
Research and Development Expense
Unamortized issuance costs and transaction costs.
Unamortized Issuance Costs and Transaction Costs
Less: Unamortized issuance costs and transaction costs
Cumulative Currency Translation Adjustment Attributable to Divestiture
Cumulative currency translation adjustment attributable to divestiture.
Cumulative currency translation adjustment attributable to divestiture (Note 3)
Cumulative currency translation adjustment attributable to divestiture
General Purchases And Other Programs [Member]
General purchases and other programs.
General Purchases And Other Programs
General Purchases And Other Programs [Member]
Cost of Revenue, Total
Cost of goods sold
Cost of Revenue
Related cost of goods sold
Discounted Cash Flow [Member]
Valuation Technique, Discounted Cash Flow [Member]
Schedule of Investments [Abstract]
Schedule of Components of Provision For Income Taxes
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
Shares issued from stock plans, net of payroll taxes paid
Adjustments To Additional Paid In Capital Shares Issued From Stock Plans Net Of Payroll Taxes Paid
Adjustments to additional paid in capital shares issued from stock plans net of payroll taxes paid.
Statement of Cash Flows [Abstract]
Future manufacturing clinical regulatory and commercial milestone payments
Future Manufacturing Clinical Regulatory And Commercial Milestone Payments
Future manufacturing clinical regulatory and commercial milestone payments.
Federal
Current Federal Tax Expense (Benefit)
Issuance of common stock under ATM Program
Stock Issued During Period, Value, New Issues
Issuance cost under ATM Program
Summary of Stock Option Transactions
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
Stock based compensation
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent
Net Loss Per Share
Earnings Per Share [Text Block]
Number of product development obligations
Number Of Product Development Obligations
Number of product development obligations.
Unrecognized tax benefits that would affect effective tax rate
Unrecognized Tax Benefits that Would Impact Effective Tax Rate
Discontinued Operations and Disposal Groups [Abstract]
Computer Equipment [Member]
Computer Equipment [Member]
Cybersecurity Risk Management Processes Integrated [Text Block]
Net income (loss)
Net income (loss)
Direct Sales [Member]
Direct Sales [Member]
Direct sales.
Outstanding, Aggregate Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Inventory write-down
Inventory Write-down
Increase (Decrease) in Inventories, Total
Inventories
Increase (Decrease) in Inventories
Series E [Member]
Series E Preferred Stock [Member]
Operating lease cost
Operating Lease, Cost
Operating leases
Income Tax Contingency [Line Items]
Income Tax Contingency [Line Items]
Lease obligations
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent
Expected dividend yield
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Revenue interest payment
Revenue interest payment.
Acquisition And Variable Interest Entity [Line Items]
Acquisition And Variable Interest Entity [Line Items]
Acquisition and variable interest entity line items.
Beijing Falikang Pharmaceutical Co. Ltd [Member]
Beijing Falikang Pharmaceutical Co Ltd
Beijing Falikang Pharmaceutical Co Ltd [Member]
Beijing Falikang Pharmaceutical Co. Ltd.
Value added taxes and other taxes
Accrual for Taxes Other than Income Taxes, Current
Operating cash flows from operating leases
Cash payment related to lease
Operating Lease, Payments
Assets
Assets [Abstract]
Risk-free interest rate
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Construction in progress [Member]
Construction in Progress [Member]
Increase (Decrease) in Prepaid Expense and Other Assets
Prepaid expenses and other current assets
Dividend received from unconsolidated variable interest entity.
Dividend Received from Unconsolidated Variable Interest Entity
Dividend received from unconsolidated variable interest entity
2027
Revenue Payment Cap Amount Due In Year Five
Revenue payment cap amount due in year five.
Commercial paper
Commercial Paper, at Carrying Value
Document Fiscal Year Focus
Document Fiscal Year Focus
Liability related to sale of future revenues, non-current
Liability Related To Sale Of Future Revenues Non Current
Liability related to sale of future revenues non current.
Concentration Risk Benchmark
Concentration Risk Benchmark [Domain]
Investing activities
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]
Accounts payable
Accounts Payable, Current, Total
Accounts Payable, Current
Research and development [Member]
Research and Development Expense [Member]
Geographic Distribution
Geographic Distribution [Domain]
Gain (Loss) on Disposition of Business
Gain on divestiture
Gain on divestiture
Roll-forward of Related Contract Liabilities
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]
Federal
Deferred Federal Income Tax Expense (Benefit)
Disposal Group Including Discontinued Operation Other Liabilities current
Disposal group including discontinued operation other liabilities current.
Operating lease liabilities, current
Other tax credit carryforwards expiration year
Other Tax Credit Carryforwards Expiration Year
Other tax credit carryforwards expiration year.
Schedule of Prepaid Expenses and Other Current Assets
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]
Transaction Type
Transaction Type [Axis]
Research And Pre Clinical Stage Development Programs [Member]
Research and pre-clinical stage development programs.
Research and Preclinical Stage Development Programs
Revision of Prior Period [Domain]
Lessee, finance lease, option to extend the additional lease term
Lessee Finance Lease Option To Extend Additional Lease Term
Lessee, finance lease, option to extend the additional lease term.
Net contract assets
Net unbilled co-development revenue
Supplies Net
Supplies, net.
Net unbilled milestone and co-development revenue
Aggregate considerations received excluding drug product revenue
Collaborative Arrangement Aggregate Consideration Excluding Drug Product Revenue
Amount of aggregate consideration receivable under collaborative arrangement excluding drug product revenue.
RSUs, PRSUs and TSR awards [Member]
RSUs, PRSUs and TSR Awards [Member]
RSUs, PRSUs and TSR Awards [Member]
Fair Value Measurements
Fair Value Measurement, Policy [Policy Text Block]
Bond and mutual funds [Member]
Bond And Mutual Funds [Member]
Bond and mutual funds.
Other Liabilities, Total
Other Liabilities
Due to related parties
Schedule of Activity of Liability Related to Sale of Future Royalties
Schedule of activity of liability related to sale of future royalties [Table Text Block]
Schedule of activity of liability related to sale of future royalties.
Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]
Warrants to purchase common stock exercised
Class Of Warrant Or Right Number Of Warrants Or Rights Exercised During Period
Class of warrant or right number of warrants or rights exercised during period.
Fair Value Disclosures [Abstract]
Commitments and Contingencies Disclosure [Abstract]
Lease Termination Settlement Amount One Time Payment
Lease termination settlement amount one time payment.
Lease termination settlement one time cash payment
Tax credits, Amount
Effective Income Tax Rate Reconciliation, Tax Credit, Amount
Effective Income Tax Rate Reconciliation, Tax Credit, Amount, Total
Lessee, Operating Lease, Liability, to be Paid, Year One
2024
Disposal group including discontinued operation additional payment related to first holdback
Disposal group including discontinued operation additional payment related to first holdback.
Third party shareholders.
Third Party Shareholders [Member]
Interest expense
Interest expense
Disposal Group, Including Discontinued Operation, Interest Expense
Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]
Effective Income Tax Rate Reconciliation [Line Items]
Astellas Japan Agreement [Member]
Astellas Japan Agreement [Member]
Astellas Japan Agreement.
Variable consideration related to payments for milestones considered probable of being achieved
Variable Consideration Payment Received Upon Achievement Of Milestone
Variable consideration payment received upon achievement of milestone.
Lease termination, remaining security deposit
Long-Term Line of Credit
Long-Term Line of Credit, Total
Contract with Customer, Asset, after Allowance for Credit Loss, Current, Total
Contract with Customer, Asset, after Allowance for Credit Loss, Current
Contract asset
Expiration Year Two Thousand Forty Five [Member]
Expiration year two thousand forty five.
Expiration Year 2045 [Member]
Revenue payment cap amount due in year three.
2025
Revenue Payment Cap Amount Due In Year Three
Proceeds from upfront, non-contingent and non-refundable payments
Proceeds From Upfront Non Contingent And Non Refundable Payments
Represents the total amount of non-contingent, non-refundable, upfront payments included under the collaborative agreement as arrangement consideration.
Debt Instrument [Axis]
Beyond 2027
Lessee, Operating Lease, Liability, to be Paid, after Year Five
Share-Based Payment Arrangement [Abstract]
Total lease liabilities
Finance Lease And Operating Lease Liability
Finance lease and operating lease liability.
Assets, Fair Value Disclosure, Total
Total fair value of financial assets
Assets, Fair Value Disclosure
Roxadustat [Member]
Roxadustat Drug Product [Member]
Roxadustat drug product.
Sale of Stock
Sale of Stock [Axis]
Effective Income Tax Rate Reconciliation Worldwide Changes in Unrecognized Tax Benefits
Effective income tax rate reconciliation worldwide changes in unrecognized tax benefits.
Worldwide changes in unrecognized tax benefits, Amount
Concentration risk, percentage
Concentration Risk, Percentage
Revenues, Total
Revenue recognized
Revenues
Interest Expense, Term Loan
Interest Expense, Term Loan
Outstanding interest amount
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
Net cash provided by investing activities
Transaction price, variable consideration from estimated future co-development billing
Variable Consideration Payment Received From Estimated Future Co Development Billing
Variable consideration payment received from estimated future co-development billing.
Transfers of assets into level 3
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3
Finance leases
Finance Lease, Weighted Average Remaining Lease Term
Title of 12(b) Security
Title of 12(b) Security
Schedule Of Segment Reporting Information By Segment [Table]
Schedule of Segment Reporting Information, by Segment [Table]
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount
Stock based compensation, Amount
Forfeited, Weighted Average Exercise Price per Share
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Forfeited, Weighted Average Fair value at Grant
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Money market funds [Member]
Money Market Funds [Member]
Related Party
Related and Nonrelated Parties [Domain]
Income Taxes
Income Tax Disclosure [Text Block]
Federal and State [Member]
Federal And State [Member]
Federal and state.
Restructuring charge.
Restructuring Charge
Restructuring Charge [Policy Text Block]
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Total interest and other, net
Total interest and other, net
Disposal Group Including Discontinued Operation Interest And Other Net
Disposal group including discontinued operation interest and other net.
Total interest and other, net
Total other long-term liabilities
Other Liabilities, Noncurrent
Other long-term liabilities
Other long-term liabilities
Finance lease right-of-use assets
Total finance lease right-of-use assets
Finance lease right-of-use assets, net
Finance lease right-of-use assets
Finance Lease, Right-of-Use Asset, after Accumulated Amortization
Legal Entity
Legal Entity [Axis]
Changes in operating assets and liabilities:
Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]
Schedule of Property and Equipment
Property, Plant and Equipment [Table Text Block]
Outstanding, Beginning Balance, Weighted Average Exercise Price per Share
Outstanding, Ending Balance, Weighted Average Exercise Price per Share
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Income Tax Disclosure [Abstract]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]
Fair Value, Recurring and Nonrecurring [Table]
Unrecognized tax benefits
Beginning balance
Ending Balance
Unrecognized Tax Benefits
Additional Paid-in Capital [Member]
Additional Paid-in Capital [Member]
Agency bonds [Member]
Bonds [Member]
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Accrued and other liabilities
Preferred shares issued, price per share
Preferred Shares Issued Price Per Share
Preferred shares issued, price per share.
Transaction price and allocated to performance obligations
Transaction Price Allocated To Performance Obligations
Transaction price allocated to performance obligations.
Measurement Frequency
Measurement Frequency [Domain]
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]
Nonmonetary Transaction Type [Domain]
Income Statement Location
Statement of Income Location, Balance [Axis]
Trading Symbol
Trading Symbol
Liability related to sale of future revenues - ending balance
Liability related to sale of future revenues - beginning balance
Liability Related To Sale Of Future Revenues
Liability related to sale of future revenues.
Clinical Trial Accruals
Clinical Trial Accrual Policy [Text Block]
Clinical trial accrual.
All other [Member]
All Other [Member]
All other.
Foreign statute of limitation generally remains open in the year
Open Tax Year
Schedule Of Related Party Transactions By Related Party [Table]
Related Party Transaction [Table]
Risk-free interest rate, maximum
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Unrecognized tax benefits description
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Estimated Range Not Possible
Disposal group, including discontinued operation, derecognition of net equity
Disposal group, including discontinued operation, derecognition of net equity.
Discontinued operation derecognition of net equity
Subsequent Event Type [Axis]
Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current
Prepaid expenses and other current assets
Employee-related Liabilities, Current, Total
Payroll and related accruals
Employee-related Liabilities, Current
Financing activities
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]
Lessee, finance lease, initial lease term
Lessee, Finance Lease, Term of Contract
Expected term (in years)
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term
Fair Value, Measurements, Recurring [Member]
Fair Value, Recurring [Member]
Schedule of Supplemental Cash Flow Information Related to Leases
Schedule Of Supplemental Cash Flow Information Related To Leases Table [Text Block]
Schedule of supplemental cash flow information related to leases.
Total future lease payments
Lessee, Operating Lease, Liability, to be Paid
Schedule of Assumptions used to Estimate Fair Value of TSR Awards
Schedule of share based payments award total shareholders return [Table Text Block]
Schedule of share based payments award total shareholders return.
Less: Interest
Lessee, Operating Lease, Liability, Undiscounted Excess Amount
ASC 842 [Member]
Accounting Standards Update 2019-01 [Member]
Long term Investments Maturity
Long Term Investments Minimum Maturity Period
Long term investments minimum maturity period.
Equity Components
Equity Components [Axis]
Weighted-average discount rate:
Weighted Average Discount Rate [Abstract]
Weighted-average discount rate.
Other Revenue [Member]
Other Revenue.
Nonoperating Income (Expense), Total
Interest income and other income (expenses), net
Nonoperating Income (Expense)
Equity Component
Equity Component [Domain]
Deferred revenue
Deferred Tax Assets, Deferred Income
Valuation Allowances for Deferred Tax Assets [Member]
SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]
Business Combination, Recognized Asset Acquired and Liability Assumed [Table Text Block]
Schedule of Allocation of Purchase Consideration Based on Estimated Fair Values of Acquired Assets
Document Annual Report
Document Annual Report
Profit share percent
Profit Share Percent
Profit share percent.
Business Acquisition
Business Combination [Axis]
Redeemable Preferred Stock Member
Redeemable Preferred Stock [Member]
Redeemable [Member]
Acquired in-process research and development asset
Acquired In Process Research And Development Asset
Acquired in process research and development asset.
Disposal Group Including Discontinued Operation Research And Development Expense
Disposal group including discontinued operation research and development expense.
Research and development
IPO [Member]
IPO [Member]
Machinery [Member]
Machinery and Equipment [Member]
Percentage of joint development costs committed to fund
Percentage Of Funding For Costs
Represents the percentage of costs that will be funded by the other party under a collaborative agreement for development costs.
Shares purchased by employees
Stock Issued During Period, Shares, Employee Stock Purchase Plans
Expiration period of stock options
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period
Disposal Group Including Discontinued Operation Operating Lease Right Of Use Asset Noncurrent
Disposal group including discontinued operation operating lease right of use asset noncurrent.
Operating lease right-of-use assets
Additions
Contract With Customer Liability Additions
Contract with customer liability additions.
Cash And Cash Equivalents And Restricted Time Deposits Policy Policy [Text Block]
Cash and cash equivalents and restricted time deposits policy.
Cash, Cash Equivalents
U.S. government bonds [Member]
US Treasury and Government [Member]
Warrants exercised
Warrants Exercised During Period Value
Warrants exercised during period value.
Common stock voting rights
Common Stock, Voting Rights
Statement of Comprehensive Income [Abstract]
Equity Method Investment, Nonconsolidated Investee
Equity Method Investment, Nonconsolidated Investee [Axis]
Maximum [Member]
Maximum [Member]
Collaboration agreement payment
Collaboration agreement payment.
Collaboration agreement payment
Statistical Measurement
Statistical Measurement [Axis]
Deferred revenue, net of current
Contract with Customer, Liability, Noncurrent
Deferred revenue, net of current
Prepaid Expense, Current, Total
Prepaid assets
Prepaid Expense, Current
Common Stock, Value, Issued
Common stock, $0.01 par value; 225,000 shares authorized at December 31, 2025 and 2024; 4,047 and 4,037 shares issued and outstanding at December 31, 2025 and 2024
Disposal Group Including Discontinued Operation Costs And Expenses [Abstract]
Disposal group including discontinued operation costs and expenses.
Operating costs and expenses:
Cash and Cash Equivalents [Abstract]
Balance
Balance
Equity, Including Portion Attributable to Noncontrolling Interest
Total deficit
Non-contingent upfront payments received
Proceeds From Non Contingent Upfront Payments
Represents the amount of non-contingent upfront payments included under the collaborative agreement as arrangement consideration.
Royalty Revenue [Member]
Royalty [Member]
2024
Revenue Payment Cap Amount Due In Year Two
Revenue payment cap amount due in year two.
Income Tax Contingency [Table]
Income Tax Contingency [Table]
U.S./RoW and China [Member]
U.S./RoW and China [Member]
United States Rest Of World And China [Member]
United States/Rest of World and China.
Eluminex Agreements [Member]
License Agreement With Eluminex [Member]
License agreement with Eluminex.
Eluminex [Member]
Transfers of assets from level 1 to 2
Fair Value Assets Level1 To Level2 Transfer Amount
Fair value assets level1 to level2 transfer amount.
Income (Loss) from Continuing Operations, Per Diluted Share
Loss from continuing operations per share - diluted
Deferred Tax Assets, Operating Loss Carryforwards, Total
Federal and state net operating loss carryforwards
Deferred Tax Assets, Operating Loss Carryforwards
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]
Impairment of Long-Lived Assets
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]
Accrued liabilities
Accrued Liabilities
Accrued Liabilities, Total
Co-development services related to CDK continued over development year
Co Development Services Related To C D K Continued Over Development Year
Co-development services related to CDK continued over development year.
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent
State tax, net of federal benefit
Amortization of Debt Issuance Costs
Amortization of issuance costs
Right-of-use assets cost
Finance Lease Right Of Use Assets Cost
Finance lease, right-of-use assets - cost.
Entity Public Float
Entity Public Float
Expected volatility
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Preferred stock, shares authorized
Preferred Stock, Shares Authorized
Total operating costs and expenses
Costs and Expenses
Finite-Lived Intangible Assets by Major Class
Finite-Lived Intangible Assets by Major Class [Axis]
Cash paid for payroll taxes on restricted stock unit releases
Payment, Tax Withholding, Share-Based Payment Arrangement
Liability Related to Sale of Future Royalties [Abstract]
Liability related to sale of future royalties.
Available for sale securities in continual unrealized loss position, gross unrealized holding losses
Available for sale securities in continual unrealized loss position, gross unrealized holding losses
Available for sale securities in continual unrealized loss position, gross unrealized holding losses
Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss
Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss, Total
Astellas [Member]
Astellas [Member]
Astellas.
Reverse Stock Split
Reverse Stock Split [Policy Text Block]
Reverse stock split.
Related Party Transaction [Line Items]
Related Party Transaction [Line Items]
ESPP [Member]
Employee Stock [Member]
Variable consideration related to profit share
Variable Consideration Related To Profit Share
Variable consideration related to profit share.
Business Combination [Table]
Schedule of Allocation of Purchase Consideration Based on Estimated Fair Values of Acquired Assets
Increase Decrease In Prepaid Expenses And Other Current Assets Related Parties
Prepaid expenses and other current assets from related party
Increase decrease in prepaid expenses and other current assets related parties.
Entity Registrant Name
Entity Registrant Name
Debt Disclosure [Text Block]
Senior Secured Term Loan Facilities
Gross Unrealized Holding Losses
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Entity Voluntary Filers
Entity Voluntary Filers
Customer Concentration Risk [Member]
Customer Concentration Risk [Member]
Cayman Islands
CAYMAN ISLANDS
Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized
Changes in revenue from changes to estimated variable consideration
Lease termination settlement amount
Lease Termination Settlement Amount
Lease termination settlement amount.
Operating and finance lease payment obligations
Operating And Finance Lease Payment Obligations
Operating and finance lease payment obligations.
Additional Paid in Capital, Total
Additional paid-in capital
Additional Paid in Capital
State
Deferred State and Local Income Tax Expense (Benefit)
Series D [Member]
Series D Preferred Stock [Member]
No Later Than December 31, 2030 [Member]
Payment Period Two [Member]
Payment period two.
Payment Period Two [Member]
Subsequent Events [Abstract]
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Cybersecurity Risk Management Positions or Committees Responsible [Flag]
Income Tax Expense (Benefit)
Benefit from income taxes
Benefit from income taxes
Measurement Frequency
Measurement Frequency [Axis]
Proceeds from Issuance of Common Stock
Proceeds from issuance of common stock under employee stock plans
Proceeds from sale of common stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Impairment Loss On Debt Securities Available For Sale
Impairment loss on debt securities available for sale.
Impairment loss
U.S. government bonds [Member]
U S Government Bonds [Member]
U.S. government bonds.
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Concentration of Credit Risk
Concentration Risk, Credit Risk, Policy [Policy Text Block]
Accumulated Other Comprehensive Income (Loss), Net of Tax, Total
Accumulated other comprehensive loss
Accumulated Other Comprehensive Income (Loss), Net of Tax
Cash payments for restructuring
Payments for Restructuring
Payments to Acquire Property, Plant, and Equipment, Total
Purchases of property and equipment
Payments to Acquire Property, Plant, and Equipment
Granted, Shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period
Schedule of Drug Product Revenue
Schedule Of Drug Product Revenue Table [Text Block]
Schedule of drug product revenue.
Senior secured term loan facilities, non-current
Secured Long-Term Debt, Noncurrent
Other tax credit carryforwards
Deferred Tax Assets, Tax Credit Carryforwards, Other
Total assets
Assets
Inventories
Inventory, Policy [Policy Text Block]
Schedule Of Property Plant And Equipment [Table]
Property, Plant and Equipment [Table]
Exercisable, Weighted Average Remaining Contractual Life
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term
Income Statement [Abstract]
Percentage of revenue sold
Percentage of revenue sold.
Charged to Other Accounts - Liabilities and Equity
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account
Right-of-use assets cost
Operating Lease Right Of Use Assets Cost
Operating lease, right-of-use assets - cost.
Other
Effective Income Tax Rate Reconciliation, Cross-Border, Other, Percent
Operating cash flows from finance leases
Finance Lease, Interest Payment on Liability
Fair Value of Financial Instruments
Fair Value of Financial Instruments, Policy [Policy Text Block]
Decrease due to prior positions
Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions
Stock-Based Compensation
Share-Based Payment Arrangement [Policy Text Block]
Total deferred
Deferred Income Tax Expense (Benefit)
Selling, general and administrative [Member]
Selling, General and Administrative Expenses [Member]
Selling, General and Administrative Expenses [Member]
Delayed draw term loan two.
Delayed Draw Term Loan Two [Member]
Delayed Draw Term Loan 2
Global intangible low-taxed income
Global intangible low-taxed income
Effective Income Tax Rate Reconciliation, GILTI, Percent
Issuance of common stock under ATM Program shares
Stock Issued During Period, Shares, New Issues
Finance lease cost:
Lease, Cost [Abstract]
Recorded Unconditional Purchase Obligation
Recorded Unconditional Purchase Obligation, Total
Recorded unconditional purchase obligation
Vested, Shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Consolidation, Variable Interest Entity, Policy [Policy Text Block]
Variable Interest Entity
Variable Interest Entity
Amortization of debt issuance costs and related transaction costs.
Amortization of Debt Issuance Costs and Related Transaction Costs
Issuance costs and related transaction costs, amortised
Royalty rate against projected net revenues
Royalty Rate On Net Revenue
Implied royalty rate used to find the net present value of future cash flows.
Business Combination [Abstract]
License Acquisition Agreement
License Acquisition Agreement Policy Policy [Text Block]
License acquisition agreement policy.
Net loss per share - diluted
Earnings Per Share, Diluted
Net income (loss) per share - diluted
Premium and fees
Premiums and Other Receivables, Net
Prepayment premium and fees
Conversion Of Subsidiarys Convertible Note Payable
Conversion of subsidiary's convertible note payable.
Conversion of subsidiary's convertible note payable(Note 13)
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Disaggregation of Revenue [Abstract]
City Area Code
City Area Code
FibroGen Beijing [Member]
Fibro Gen Beijing [Member]
FibroGen Beijing.
Income Taxes [Line Items]
Income Taxes [Line Items]
Income taxes line items.
Other Comprehensive Income (Loss), Net of Tax
Other comprehensive income, net of taxes
Currency Translation and Other
Contract With Customer Liability Increase Decrease From Current Translation And Other
Contract with customer, liability, increase (decrease) from current translation and other.
Auditor Name
Auditor Name
Discontinued operation cash paid at closing
Disposal Group, Including Discontinued Operation, Cash Paid at Closing
Disposal group, including discontinued operation, cash paid at closing.
Total payments
Revenue payment cap amount
Revenue Payment Cap Amount
Revenue payment cap amount.
Paid to lenders
Debt Instrument, Fee Amount
Paid to the Lenders
Discontinued Operation, Tax Effect of Discontinued Operation
Provision for income taxes
Income from discontinued operations, net of tax
Finance lease liabilities, non-current
Finance lease liabilities
Finance lease liabilities, non-current
Finance Lease, Liability, Noncurrent
Manufacture And Supply Of FG Three Two Four Six
Manufacture And Supply Of FG Three Two Four Six [Member]
Manufacture and supply of FG three two four six.
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
Income from discontinued operations, net of tax
Income from discontinued operations, net of tax
Business Combination [Line Items]
Deferred Tax Assets, Tax Credit Carryforwards, Total
Tax credit carryforwards
Deferred Tax Assets, Tax Credit Carryforwards
Counterparty Name [Domain]
Schedule Of Entity Wide Revenue By Major Customers By Reporting Segments [Table]
Schedule of Revenue by Major Customers, by Reporting Segments [Table]
Foreign government bonds [Member]
Foreign Government Debt [Member]
Product revenue from a related party
Product Revenue
Product revenue from a related party.
Operating leases
Operating Lease, Weighted Average Remaining Lease Term
Segment Reporting Information [Line Items]
Segment Reporting Information [Line Items]
Disposal Group Name [Axis]
Total lease cost
Lease, Cost
Award Date [Axis]
Cash and Cash Equivalents, Policy [Policy Text Block]
Cash, Cash Equivalents
Percentage of tiered royalties receivable.
Percentage of Tiered Royalties Receivable
Percentage of tiered royalties receivable
Accounts payable from related party
Increase Decrease In Accounts Payable From Related Party
Increase decrease in accounts payable from related party.
Property and equipment, net
Property and equipment, net
Property, Plant and Equipment, Net
Property and equipment
Finance leases
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability
Transfer price true up
Transfer Price True Up
Transfer price true up.
Foreign
Deferred Foreign Income Tax Expense (Benefit)
Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent
Total long-term liabilities held for sale
Long-term liabilities held for sale
Impairment of inatangible assets finite lived
Impairment of Intangible Assets, Finite-Lived
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total
Total cash and cash equivalents at beginning of period
Total cash and cash equivalents at end of period
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
Total cash and cash equivalents in the consolidated statements of cash flows
Corporate bonds [Member]
Corporate Bond Securities [Member]
Loss from operations
Operating Income (Loss)
Award Date [Domain]
Retained Earnings [Member]
Accumulated Deficit [Member]
Schedule of Activity of Liability Related to Sale of Future Revenues
Schedule Of Activity Of Liability Related To Sale Of Future Revenues [Table Text Block]
Schedule of activity of liability related to sale of future revenues.
Transaction
Transaction [Domain]
Share-Based Payment Arrangement, Noncash Expense, Total
Stock-based compensation
Share-Based Payment Arrangement, Noncash Expense
Maximum additional future clinical, regulatory, and commercial milestone payments
Maximum Additional Future Clinical Regulatory And Commercial Milestone Payments
Maximum additional future clinical regulatory and commercial milestone payments.
Available for sale securities in continual unrealized loss position, less than 12 months, estimated fair value
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months
Operating leases
Operating Lease, Weighted Average Discount Rate, Percent
Operating lease liabilities
Operating lease liabilities, non-current
Operating Lease, Liability, Noncurrent
Level 1 [Member]
Fair Value, Inputs, Level 1 [Member]
Redemption of Fractional Shares Due to Reverse Stock Split
Redemption of fractional shares due to reverse sock split.
Redemption of fractional shares due to reverse stock split, Shares
Redemption of fractional shares due to reverse stock split, Shares
Class Of Stock [Line Items]
Class of Stock [Line Items]
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Net cash used in financing activities
Components of Lease Expense
Lease, Cost [Table Text Block]
Auditor Location
Auditor Location
Lessee, finance lease, additional lease expiration period
Lessee Finance Lease Additional Lease Expiration Period
Lessee, finance lease, additional lease expiration period.
Distribution to non-controlling interest (Note 12)
Noncontrolling Interest, Increase (Decrease) from Distributions to Noncontrolling Interest Holders
Noncontrolling interest, increase (decrease) from distributions to noncontrolling interest holders.
FINLAND
Finland
Deferred tax asset for temporary difference
Deferred Tax Asset, Intra-Entity Transfer, Asset Other than Inventory
Interest and other, net
Nonoperating Income (Expense) [Abstract]
Bulk Drug Product
Bulk Drug Product [Member]
Bulk drug product.
Bulk Drug Product [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Manufacture And Supply Of Roxadustat
Manufacture and Supply of Roxadustat.
Manufacture And Supply Of Roxadustat [Member]
Manufacture and Supply of Roxadustat [Member]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Schedule of Weighted Impacts of Outstanding Anti-dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share
Foreign net operating loss carryforwards
Deferred Tax Assets, Operating Loss Carryforwards, Foreign
Income Tax Authority
Income Tax Jurisdiction [Domain]
Debt Securities, Available-for-Sale [Table]
Entity Interactive Data Current
Entity Interactive Data Current
Increase (Decrease) in Contract with Customer, Liability
Deferred revenues
Income Statement Location
Statement of Income Location, Balance [Domain]
Operating activities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]
Furniture and Fixtures [Member]
Furniture and Fixtures [Member]
Conversion rights, shares issued upon conversion of each preferred share
Convertible Preferred Stock, Shares Issued upon Conversion
Maximum Research and Development and Regulatory Milestone Payments Receivable
Maximum Research and Development and Regulatory Milestone Payments Receivable
Maximum R&D and regulatory milestone payments receivable
Rent increase commencement year first option
Scheduled Rent Commencement Year Option One
Rent commencement year option one.
Co-promotion expenses
Co Promotion Expenses
Co-promotion expenses.
Investment income in unconsolidated variable interest entity
Investment Gain Loss In Unconsolidated Variable Interest Entity
Investment (gain) loss in unconsolidated variable interest entity.
Net accretion of premium and discount on investments
Accretion (Amortization) of Discounts and Premiums, Investments
Selling, general and administrative
Disposal Group, Including Discontinued Operation, General and Administrative Expense
Leases
Leases Disclosure [Text Block]
Leases.
RSUs, PRSUs and TSR awards [Member]
Restricted Stock Units Perfomance Based Restricted Stock Units and Total Shareholders Return [Member]
Restricted stock units perfomance based restricted stock units and total shareholders return.
Accumulated amortization
Operating Lease Accumulated Amortization
Operating lease, accumulated amortization.
Other long-term liabilities
Increase (Decrease) in Other Noncurrent Liabilities
Accrued litigation settlement
accrued litigation settlement.
Accrued Litigation Settlement
Cash paid for amounts included in the measurement of lease liabilities:
Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]
Cash paid for amounts included in the measurement of lease liabilities.
Cumulative Effect, Period of Adoption
Cumulative Effect, Period of Adoption [Domain]
Holdback Consideration Receivable Divestiture
Holdback consideration receivable divestiture.
Holdback consideration receivable related to divestiture in prepaid expenses and other current assets
Accrued interest for finance lease liabilities
Increase Decrease In Accrued Interest For Finance Lease Liabilities
Increase (decrease) in accrued interest for finance lease liabilities.
Entity Tax Identification Number
Entity Tax Identification Number
Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]
Stockholders' deficit:
Long-Term Debt, Type [Axis]
Accounting Policy [Table]
Accounting Policy [Table]
Accounting policy.
Loss Contingency, New Claims Filed, Number
Number of complaints filed
Deferred Tax Liabilities Non Deductibale Accrued Expenses
Deferred tax liabilities non deductibale accrued expenses.
Non-deductible accrued expenses
Non-deductible accrued expenses
Local Phone Number
Local Phone Number
Other Purchases.
Other Purchases [Member]
Other Purchases
Liability related to sale of future revenues current.
Liability Related To Sale Of Future Revenues Current
Current portion of liability related to sale of future revenues
Unrecognized compensation costs
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
China [Member]
CHINA
Auditor Opinion [Text Block]
Finance Lease, Liability, to be Paid, Year Two
2025
Payment of issuance cost under ATM Program
Payments of Financing Costs
Payments of Financing Costs, Total
Accounting Policies [Abstract]
License and Development [Member]
License And Development [Member]
License and development.
Summary of Amounts Recognized as Revenue
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]
Reclassified to accrued liability / accounts payable
Contract With Customer Liability Reclassified to Accrued Liability
Contract with customer liability reclassified to accrued liability.
Drug product revenue recognized
Total revenue
Drug product revenue recognized
Astra Zeneca
Astra Zeneca [Member]
AstraZeneca.
Outstanding interest and related premium and fees
Outstanding interest and related premium and fees
Outstanding interest and related premium and fees.
Lessee, Operating Lease, Liability, to be Paid, Year Four
2027
Class of Stock
Class of Stock [Domain]
Commercial paper [Member]
Commercial Paper [Member]
Shares reserved for future stock options and RSUs grant
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant
Non-vested stock option awards granted that will be recognized on a straight-line basis over the weighted-average period
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition
Percentage of royalty payment on global net sales
Percentage of royalty payment on global net sales.
Office Equipment [Member]
Office Equipment [Member]
Professional services
Accrued Professional Fees, Current
Schedule Of Stock By Class [Table]
Stock, Class of Stock [Table]
Weighted-average remaining lease term (years):
Weighted Average Remaining Lease Term [Abstract]
Weighted-average remaining lease term.
Entity Emerging Growth Company
Entity Emerging Growth Company
Vested and expected to vest, Weighted Average Remaining Contractual Life
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term
Disposal Group, Including Discontinued Operation, Operating Income (Loss)
Income from operations